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MUTATIONS IN A MECHANOSENSITIVE CHANNEL ENABLE 
INTRAVASCULAR METASTSTIC CELL SURVIVAL 
 
Paul William Furlow, Ph.D. 
The Rockefeller University 2014 
Next-generation sequencing technology has revolutionized cancer biology 
by accelerating the unbiased discovery of mutations across human cancers1-4. 
Despite this advance, it remains unknown whether there exist mutations that 
function specifically to drive steps in the metastatic cascade independent from, or 
perhaps even to the detriment of, tumor initiation and growth5. The development 
and implementation of a discovery framework that integrates next-generation 
RNA-sequencing with in vivo selection, has identified recurrent non-synonymous 
amino acid mutations that are enriched in metastatic breast cancer cells and 
predicted to significantly alter protein function. The pro-metastatic role of one of 
these mutations—a nonsense alteration that yields a truncated pannexin-1 
(PANX11-89) plasma membrane megachannel subunit—was functionally 
characterized. PANX11-89 forms a multimeric complex with wild-type PANX1 at 
the plasma membrane and augments PANX1 channel activity to promote cancer 
cell survival soon after cells enter the microvasculature of metastatic target 
organs, where they become physically deformed within vessels. Enhanced ATP 
release from PANX1 channels, which are activated during membrane stretch, 
acts as a cell autonomous survival signal during lethal cellular deformation. 
Functional characterization of additional nonsense and missense PANX1 
	 5
mutations detected in epithelial cancers of the colon, lung, and prostate reveals 
that these mutations also enhance PANX1-mediated ATP release. One such 
truncating colorectal cancer variant is also shown to promote survival during 
cellular deformation as well as in vivo intravascular survival, dissemination and 
metastatic liver colonization by colon cancer cells.  Finally, pharmacological 
treatment of mice with a PANX1 inhibitor suppresses breast cancer metastasis to 
the lungs, implicating PANX1 as a therapeutic target in cancer. These findings 
reveal that mutational augmentation of PANX1 channel activity during 
mechanical trauma enables cancer cells to overcome a major metastasis 
suppressive barrier—cell death in the microvasculature. 
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CHAPTER I: INTRODUCTION 
Despite significant advances in mammographic screening, surgery and 
medical therapy, breast cancer remains a tremendously devastating problem. It 
is consistently the leading cancer among females in the United States6, predicted 
to afflict one out of every eight US women over the course of their lives1. 
Fortunately, early identification and treatment of a localized mass provides a 
relative 5-year survival rate of 98.6%6. However, if at the time of diagnosis the 
cells within the primary tumor have already acquired the ability to metastasize, or 
disseminate through the body to form secondary tumors in distal organs, this rate 
drops to 23.3%6. In fact, 90% of all solid tumor-related deaths are caused by 
metastasis, not primary tumor burden7. These statistics highlight the need for 
additional research into the molecular basis of metastasis. By asking whether 
specific genetic changes exist that function to promote metastatic dissemination 
and colonization independent from, or perhaps even to the detriment of, 
tumorigenesis, the cellular mechanisms that result in the majority of cancer-
related death may be revealed. An understanding of these mechanisms may 
offer a new opportunity for the development of therapeutic agents that can 
effectively prolong the life, in both duration and quality, of those cancer patients 
otherwise without curative options.   
The metastatic process would seem to be an impossible journey for a 
single cell to complete. To leave its origin in the primary tumor and travel through 
the bloodstream to take up residence in a noncontiguous organ, a malignant cell 
must successfully overcome a number of challenges. The ability to complete this 
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stepwise sequence of events, known as the “metastatic cascade”, requires a 
primary tumor cell to be fully equipped to invade through the extracellular matrix, 
migrate towards the blood vessels or lymphatics, intravasate into those vessels, 
survive embolization in the circulation, adhere to small vessels at the secondary 
site, extravasate into the secondary organ, survive the foreign microenvironment, 
and reinitiate unregulated proliferation for secondary tumor growth7 (Fig. 1). It is 
remarkable that a successful metastatic cell harbors a genetic landscape that 
grants it each and every one of the countless phenotypes required to complete 
this journey3. For this reason, metastasis is accomplished by only the 
subpopulations of cells within a primary tumor that possess all of the traits 
required to complete the process8-10. It is then critical to understand how such 
traits are acquired through genetic and/or epigenetic alterations that arise over 
the evolution of a metastatic primary tumor. 
Somatic mutations arise at random in every cell that divides. Normally, 
these alterations are repaired, otherwise the afflicted cell undergoes apoptosis1. 
In rare instances, a mutation will persist and provide the cell with a growth 
advantage by altering the function of a protein that is crucial for key cell biological 
processes, such as cell cycle regulation, differentiation, apoptosis or DNA 
repair5,9. Genes affected by such mutations are classified as oncogenes or tumor 
suppressors5. A selective proliferative advantage results when a spontaneous 
mutation “turns-on” an oncogene or “turns-off” a tumor suppressor. Mutations of 
this nature, often referred to as “driver mutations”, promote the clonal expansion 
of the cell without regard to the  
	 3
	
		
 
Figure 1. The steps of metastasis. The selective process a primary tumor cell 
must be genetically equipped to complete in order to successfully metastasize 
and colonize distant organs such as the lungs (left-to-right). Each step in the 
process acts as a selective bottleneck due to the physical and molecular 
demands on the cancer cell as well as the characteristics of the external 
environment. For this reason, the formation of metastases can be prevented at 
many points along a cell’s journey, suggesting that the ability to metastasize 
must be inherent in cells at the primary tumor site.  
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Figure 2. The mutationally driven clonal expansion of tumors. a, The 
random acquisition of driver mutations (D1-4) alters the evolutionary trajectory of 
dividing cells, thereby creating subclones with unique traits (A, B). b, Successive 
waves of proliferative driver mutations result in accelerated cell division causing 
the expansion of subclones that comprise a tumor. When tumors acquire the 
ability to invade through the basement membrane they become carcinomas. Late 
in cancer progression, subclones arise that have acquired all the traits necessary 
to successfully metastasize. In theory, metastatic subclones may show 
unchanged, increased or even decreased rates of proliferation and therefore 
variable frequencies within a primary tumor. 
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normal tissue surrounding it11 (Fig. 2). The genetic instability inherent to this 
deregulated cell growth supports the subsequent acquisition of additional driver 
mutations within the original clone9,11 (Fig. 2). A classic example of this concept 
is illustrated by the progression of colorectal cancer, where the mutational 
inactivation of the tumor suppressor APC leads to the slow development of a 
small adenoma and the subsequent mutational activation of the KRAS oncogene 
increases the proliferative rate of cells, yielding a large adenoma5 (Fig. 3). 
Continued unchecked, proliferation results in the accumulation of additional 
random mutations that eventually grant a subclone of cells within the large 
adenoma the ability to breach the basement membrane and invade the 
surrounding stroma, at which point the tumor becomes a carcinoma5 (Figs. 2 and 
3). It is generally believed that the ability of a cell to complete each step of the 
metastatic cascade is conferred by the successive waves of mutation-driven 
clonal expansion leading to the formation of a metastatic primary tumor8 (Fig. 2). 
If this holds true, the mutations present in the highest percentage of primary 
tumor cells are likely to have been the earliest initiators of a patient’s cancer, 
whereas those found at a lower frequency would be more likely to promote the 
phenotypes characteristic of a metastatic cell2. While researchers have come to 
learn much about the mutations that provide a cell with a tumor-initiating growth 
advantage, insight into those later mutations that might act specifically to 
enhance a cell’s metastatic capacity remains limited.  
To effectively study metastasis, the cancer biologist must isolate the rare 
metastatic cells within a heterogeneous cancer cell population from the many  
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Figure 3. Mutational drivers of tumorigenesis. The process by which normal 
colonic epithelium transitions to invasive carcinoma through the acquisition of 
inactivating and activating mutations in tumor suppressors and oncogenes, 
respectively, over the lifetime of a patient. Adenomatous polyposis coli (APC) is a 
tumor suppressor that inhibits unwanted cell proliferation through the β-catenin 
pathway. KRAS, is a GTPase that promotes growth factor signaling. The age at 
which patients acquire each type of mutation is indicated at the bottom.	
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cells that cannot metastasize. In 1973, Dr. Isaiah Fidler overcame this challenge 
by applying in vivo selection to the study of metastasis12. In this model, cancer 
cells are injected into an immunocompromised mouse and allowed to 
disseminate, colonize and grow in distal organs until they form metastases12 (Fig. 
4). The resulting metastatic nodules are then harvested, expanded in vitro and 
injected into another mouse to repeat the selection process (Fig. 4). After 
multiple rounds of selection, the resulting cell line is tested to see if it forms 
metastases with greater efficacy than the parental cancer cell population from 
which it originated (Fig. 4)13,14. Once the increased metastatic ability of the 
derivative cell line is verified, the phenotypic, cell biologic, molecular and genetic 
differences between it and the parental line can be interrogated in order to 
understand the basis for its enhanced metastatic activity. A number of studies 
have successfully used this model to identify genes, transcriptional regulators, 
and post-transcriptional regulators that mediate cancer metastasis13-18. However, 
the question as to whether single base-pair mutations exist that act to specifically 
activate or inactive pro- or anti-metastatic genes, respectively, remains largely 
unanswered5.  
With the advent of next-generation sequencing, entire cancer genomes 
are now being sequenced on a daily basis19. This technology uses a quantitative  
“sequencing-by-synthesis” approach whereby fluorescently labeled dNTPs are 
imaged as they are incorporated into growing DNA strands that are 
complementary to fragments of the DNA being sequenced. By amplifying these 
fragments prior to sequencing, these platforms can produce over a billion reads  
	 9
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. In vivo selection model of metastasis. The process by which highly 
metastatic sub-lines are generated from poorly metastatic cell populations 
harvested directly from the pleural effusions of breast cancer patients. Parental 
cell lines are expanded in vitro, injected into immunocompromised mice and 
allowed to disseminate and colonize target organs. Tumors from these mice are 
then extracted, cancer cells are expanded and injected into another mouse at 
lower cell numbers to promote the selection of highly metastatic cells. 
Successive waves of selection can be performed to generate more genetically 
homogenous highly aggressive derivative sub-lines, effectively isolating the 
genetic changes driving the metastatic process. Molecular and cellular 
differences between the parental and derivative lines can then be studied.  
 
 
 
 
	10
from 50-100 base pairs in length covering the genome many times over. These 
reads are then mapped to a reference genome using a computational program 
and analyzed by a bioinformatics framework specific for the desired application, 
such as the discovery of translocations, insertions/deletions (indels) or single 
nucleotide variants (SNVs)19. The application of this technology has also been 
tailored to provide both sequence and expression data from a cell’s 
transcriptome. By quantifying the number of reads covering the transcriptome, 
RNA-sequencing (RNA-seq) can measure the expression of genes, non-coding 
RNAs, gene isoforms, splice variants as well as the frequencies of mutated 
alleles20. This technology is also optimal for the discovery of mutations in the 
protein-coding regions of only those genes that are expressed in a cell in a given 
biological context, such as metastasis. 
To date, many studies have used next-generation sequencing to survey 
the integrity of cancer genomes and transcriptomes across a wide variety of 
cancer types2. As a result, the number of genes found mutated in cancer is 
increasing at a rate faster than ever before. However, there are a number of 
concerns raised by these studies. For one, the high cost of next-generation 
sequencing has forced many investigators to draw conclusions based on the 
sequencing of one biological sample, which can result in the discovery of rare or 
artifactual mutations. Second, while large collections of patient-matched primary 
and metastatic tumors would be the gold standard for identifying metastasis-
promoting genetic changes, metastatic tumors are not routinely resected. This is 
because the prognosis for patients with metastatic disease is so poor that the risk 
	11
and morbidity of surgery vastly outweighs the benefit of removing a metastatic 
nodule originating from a tumor that has likely seeded many other sites in the 
organs of the patient. Another major problem with current cancer sequencing 
studies is that the vast majority of large-scale cancer sequencing studies neglect 
to validate the in vivo functionality of the identified mutations. Finally, studies 
looking for metastatic drivers often sequence the DNA or RNA of primary lesions 
where any mutations residing in small subclones are overlooked (Fig. 2). Recent 
reports estimate that the false negative rate of such sequencing studies 
approaches 37%21. This is thought to be due both the technological limitations of 
current sequencing platforms5 and the contamination of cancer tissue with 
normal stromal tissue that effectively drowns out the low-frequency mutations 
residing in a relatively small number of tumor cells22.  
Based on the well-established role for non-synonomous mutations in 
causing the cellular phenotypes responsible for tumorigenesis, this study began 
with the hypothesis that there are functional non-synonomous single nucleotide 
variants (nSNVs) within malignant cells that contribute specifically to their 
metastatic capacity. Presented herein are the results of the design and 
implementation of an unbiased approach for the systematic discovery of low-
frequency nSNVs that act as drivers of metastasis. This unique framework 
integrates next-generation RNA-sequencing with the in vivo selection of highly 
metastatic cells to overcome the current challenges of identifying low frequency 
cancer metastasis drivers and has led to the discovery of activating mutations in 
a large plasma membrane channel that drive metastasis. The characterization of 
	12
this mutation has provided insights into the molecular basis for metastatic cell 
survival during membrane stretch within the microvasculature.  
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CHAPTER II: THE SYSTEMATIC DISCOVERY OF RECURRENT NON-
NEUTRAL nSNVs ENRICHED IN HIGHLY METASTATIC BREAST CANCER 
To systematically identify mutations present in metastatic cells that may 
drive cancer progression, whole-transcriptomic RNA-seq was performed on the 
in vivo-selected13,14 highly metastatic human breast cancer cell sub-lines, CN-
LM1A and MDA-LM2, and the CN34 and MDA-MB-231 parental lines from which 
they were derived (Fig. 5 and Table 1). To minimize the false positive rate and 
allow for subsequent statistical analyses, biological replicates of each cell line 
were sequenced. The rationale for this approach was based on the hypothesis 
that allelic frequencies of mutations conferring enhanced metastatic capacity 
would likely be enriched in the transcriptomes of highly metastatic sub-lines 
relative to the transcriptomes of their less metastatic parental populations. To 
focus these efforts on the nSNVs most likely to promote metastasis, low-
confidence variants were systematically excluded by removing known 
polymorphisms, low coverage (<10✕) nSNVs, and any nSNV not detected in 
both biological RNA-seq replicates of each cell line. To identify nSNVs 
significantly enriched during metastatic selection, the differences in nSNV allelic 
frequencies between the highly metastatic sub-lines and their respective poorly 
metastatic parental lines were quantified20. The metastasis-enriched nSNVs that 
displayed an increase in allelic frequency over the four rounds of RNA-seq met 
the criteria for significance (p < 0.05, q ≤ 0.25) by a one-tailed Student’s t-test 
(Fig. 5 and Table 2). The computational tool PolyPhen-223 predicted, with high 
confidence (HumDiv score > 0.90), four of the recurrently enriched missense 
	14
variants to be non-neutral (Table 2). The genes bearing these nSNVs include the 
mitochondrial ribosome-binding factor RBFA, the transcription factor REST, the 
adherens junction regulatory factor KRIT1 and the zinc-finger-containing gene 
ZSWIM6. A single nonsense variant, PANX1 C268T, was also significantly 
enriched in both sub-lines (Table 2). Sanger sequencing of cDNA independently 
confirmed the enrichment of these mutant alleles in metastatic breast cancer 
cells (Fig. 6). These alterations represent recurrently enriched mutations and 
candidate drivers of breast cancer metastasis.  
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Figure 5. Framework for the systematic discovery of recurrent non-neutral 
nSNVs enriched in highly metastatic breast cancer. Schematic of the 
systematic discovery framework used to identify nSNVs enriched by allelic 
frequency in highly metastatic CN-LM1A and MDA-LM2 human breast cancer 
cells. 
	16
 
 
 
 
 
Table 1. RNA-seq summary	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
>9 unq reads CN-LM1A_1 CN-LM1A_2 MDA-LM2_1 MDA-LM2_2
Parental total SNVs 46848 52384 50829 45752
LM total SNVs 45288 44579 53646 42851
Common total SNVs 30533 32277 39187 33931
Parental total SNPs 4849 5073 7345 6932
LM total SNPs 4341 4153 8361 7778
Common total SNPs 3513 3522 7012 6571
Parental total nSNVs 3266 3806 3667 3419
Parental MS nSNVs 3248 3786 3645 3402
Parental NS nSNVs 18 20 22 17
LM total nSNVs 3699 3837 4120 3467
LM MS nSNVs 3675 3820 4101 3453
LM NS nSNVs 14 17 19 14
Parental non-SNP total nSNVs 755 1099 1104 880
Parental non-SNP MS 746 1088 993 871
Parental non-SNP NS 9 10 11 9
LM non-SNP total nSNVs 1253 1423 1319 899
LM non-SNP MS 1239 1415 1308 892
LM non-SNP NS 14 8 11 7
LM-enriched nSNVs 614 708 378 399
LM nSNVs in seq replicates 416 360
Recurrent 241
	17
 
 
 
 
 
Table 2. nSNVs recurrently enriched during breast cancer metastasis. 
Recurrent and non-neutral mutations identified to be significantly enriched in 
highly metastatic breast cancer cells by a one-tailed Student’s t-test (P < 0.05); n 
= 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Genomic
location
Base Amino
acid MDA-LM2CN-LM1A
p-valuefold-enrichment Protein
function
Mutated 
domain
PolyPhen 2
HumDiv
RBFA 18:75906883 G773T G258V 1.16
1.44
1.70
1.35
1.00
KRIT1 7:91668596 G1958A S701N 1.18
1.28
1.47
2.12
0.963
Mitochondrial
ribosome binding factor
Positive regulator of
integrin-β1 signaling
GatB
Rap1a 
binding
ZSWIM6 5:60861703 G1906A V636M 1.04
1.19
1.22
1.23
0.906Zinc finger
SWIM-type 6
-
PANX1 11:93526390 C268T Q90* 1.48
1.20
1.53
1.46
NonsensePlasma membrane
megachannel
ECL1
REST 4:57492601 G2821C D941H 1.23
1.09
1.08
1.28
0.987RE1-silencing
transcription factor
C-terminal 
0.0112
0.0023
0.0372
0.0473
0.0295
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Figure 6. cDNA Sanger sequencing validation of recurrently enriched non-
neutral nSNVs. Sanger sequencing traces from the cDNA of CN34, CN-LM1A, 
MDA-MB-231 and MDA-LM2 cells at the nSNV alleles predicted to result in non-
neutral substitutions by PolyPhen-2.  
	19
CHAPTER III: A NONSENSE MUTATION IN THE MECHANOSENSITIVE 
PANX1 CHANNEL PROMOTES METASTATIC CELL SURVIVAL IN THE 
MICROVASCULATURE 
Because the PANX1 C268T mutation results in an altered cell-surface 
channel protein, it was reasoned that, if functional, it might offer potential for 
therapeutic targeting. Allele-specific RNA-seq (Table 3) and Sanger sequencing 
of gDNA (Fig 7) validated the transcriptomic and genomic enrichment of the 
PANX1 C268T allele in the highly metastastatic derivative sub-lines, respectively. 
The PANX1 C268T nonsense mutation substitutes a premature termination 
codon for the glutamine codon at position 90 of the 426 amino acid PANX1 
protein, leaving only the N-terminal fragment, PANX11-89, expressed (Fig 8). 
PANX1 encodes the monomeric subunit of a heximeric plasma membrane 
channel that, when activated, mediates the release of ATP from cells into the 
extracellular space (Fig. 8)24-29—a well established autocrine/paracrine signaling 
pathway30 recently implicated in intravascular signaling during metastasis31. The 
knowledge that PANX1 homo-oligomerizes to form functional channels (Fig. 8) 
and that metastatic cells express both wild-type and mutant PANX1, suggested 
that PANX11-89 may interact with full-length PANX1. In support of this, prominent 
co-localization of PANX1 and PANX11-89 was detected at the plasma membrane 
(Fig. 9). To directly test whether PANX11-89 interacts with full-length PANX1, 
reciprocal co-immunoprecipitation experiments were performed that revealed 
PANX11-89 to associate with full-length PANX1 (Fig 10). To further confirm this 
interaction and was not an artifact of non-specific binding in vitro, the question of  
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Table 3. Allele-specific RNA-seq of the PANX1 C268T allele. Allele-specific 
RNA-seq of the PANX1 C268T allele in biological triplicates of the CN34 and 
MDA-MB-231 parental breast cancer cells and their respective lung metastatic 
derivatives, CN-LM1A and MDA-LM2. Mean enrichment was quantified by 
measuring the increase in frequency of the PANX1 C268T allele in the metastatic 
sub-lines as compared to the corresponding parental lines; n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele-specific RNA-seq
(biological triplicates) CN-LM1A MDA-LM2
Mean enrichment (%) 5.44 5.74
P-value 0.02 0.01
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Figure 7. gDNA Sanger sequencing of the PANX1 C268T allele. Sanger 
sequencing of the PANX1 mutant allele from genomic DNA of each parental and 
metastatic line. 
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Figure 8. The PANX1 megachannel. The proposed confirmation of PANX1 
monomers and homo-heximeric channels in the closed (top panel) and open 
(bottom panel) state. Association of the autoinhibitory C-terminus with the N-
terminus pore-lining first transmembrane (TM1) domain is thought to impede the 
release of ATP through PANX1. Upon activation by membrane stretch the C-
terminus is dislodged by conformational changes in the channel. During 
apoptosis, caspase cleavage of the PANX1 C-terminus releases ATP that 
functions to recruit immune cells to the site of cell death. Red arrow indicates 
position of PANX1 Q90* mutation. 
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Figure 9. Cellular localization of wild-type PANX1 and mutant PANX11-89. 
Confocal microscopy images of HEK293T cells expressing PANX1-EGFP 
(green) and PANX11-89 -mRFP (red). Co-localization at the plasma membrane is 
shown by channel overlay (yellow). 
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Figure 10. PANX11-89 associates with wild-type PANX1 to form heteromeric 
cellular complexes. a, Co-immunoprecipiation of Flag-tagged full-length 
PANX11-426 and endogenous PANX11-89 from CN-LM1A and MDA-LM2 cells. 
Anti-PANX1 N-terminal antibody detected a band similar in size to that of Flag-
tagged PANX11-89 expressed in HEK293T cells. The presence of this band in the 
metastatic sub-lines suggests that endogenous PANX11-89 associates with Flag-
tagged full-length PANX11-426. The multiple bands representing full-length PANX1 
represent the previously described glycosylated forms of PANX1. b, Co-
immunoprecipitation of PANX11-89-Flag from HEK293T cells co-transfected with 
full-length PANX11-426. Anti-PANX1 N-terminal antibody was used to detect the 
associated PANX1 species. The multiple full-length PANX1 bands represent the 
previously described glycosylated forms of PANX1. The input lysates were 
immunoblotted for PANX1. c, Increasing concentrations of DSP 
(dithiobis[succinimidyl propionate]) crosslinker were applied to HEK293T cells 
expressing Flag-tagged PANX1 prior to lysis. PANX1 complexes were detected 
using anti-FLAG M2 antibody. A complex of approximately 300 kDa represented 
the largest crosslinked PANX1 species, suggesting the ultimate formation of a 
heximeric PANX1 channel. d, Anti-PANX1 and anti-RFP immunoblotting of DSP 
crosslinked lysates from HEK293T cells expressing PANX1-EGFP, PANX1-
EGFP and PANX11-89-mRFP or PANX11-89-mRFP. The heximeric PANX1-EGFP 
channel is predicted to be approximately 480 kDa. Molecular weights are 
indicated. e, Co-immunoprecipitation of PANX11-89-RFP from protein-crosslinked 
(2mM DSP) HEK293T cells expressing PANX1-EGFP, PANX1-EGFP and 
PANX11-89-mRFP, or PANX11-89-mRFP. Anti-GFP antibody was used to detect 
the wild-type PANX1 in complex with mutant PANX11-89. Molecular weights are 
indicated.  
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whether PANX11-89 complexes with full-length PANX1 in living cells was tested by 
performing crosslinking of cellular proteins in culture. Co-immunoprecipitation of 
PANX11-89 from protein-crosslinked cells revealed that mutant protein to be 
closely associated with wild-type PANX1 in vivo (Fig. 10). Based on the sum of 
these results, it was hypothesized that the interaction between PANX11-89 and 
full-length PANX1 results in altered PANX1 channel activity. To test this, ATP 
release was measured from cells overexpressing wild-type PANX1 alone, wild-
type PANX1 and PANX11-89, or PANX11-89 alone. PANX1-mediated ATP release 
was quantified by measuring the reduction in extracellular ATP release (Fig. 11) 
in the presence of the PANX1 channel inhibitor carbenoxolone (Cbx)28,32-34 (Fig. 
12). Indeed, when co-expressed with full-length PANX1, truncated PANX11-89 
significantly enhanced extracellular ATP release through PANX1 channels (Fig. 
13a-b). ATP release was not enhanced when PANX11-89 was expressed alone in 
PANX1-deficient human cells (Fig. 13a) or PANX1-null mouse embryonic 
fibroblasts (MEFs) (Fig. 13c), suggesting that mutant PANX11-89 does not homo-
oligomerize to form functional ATP release channels. Enhanced ATP release 
caused by PANX11-89 was independent of caspase signaling, a known activator 
of PANX1 in pre-apoptotic cells28,35, as mutation of the caspase cleavage site in 
PANX1 did not impair the enhancement of ATP release (Fig. 14). Additionally, 
PANX11-89 lost the ability to augment ATP release when co-expressed with 
PANX11-297 (Fig. 15), a mutant lacking the intracellular C-terminus domain that 
has been shown to interact with the pore of the channel to impede ATP release35 
(Fig. 8), suggesting that this domain may be required for channel activation by  
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Figure 11. Luminescent standard curve for extracellular ATP concentration 
measurements. Increasing concentrations of ATP (0, 50, 100, 500 nM) were 
measured using the Cell-Titer Glo luciferase assay. 
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Figure 12. PANX1 channel inhibitor potencies. The % inhibition of 
extracellular ATP release from metastatic derivative sub-lines at one minute was 
measured in the presence of three independent PANX1 inhibitors (Probenecid, 
Cbx and 10Panx1) at varying concentrations (2 mM, 500 μM and 100 μM, 
respectively).  
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Figure 13. PANX11-89 enhances PANX1-mediated ATP release. a, 
Quantification of PANX1-mediated ATP release from HEK293T cells transfected 
with 8 μg control vector, 8 μg wild-type PANX1, 5 μg wild-type PANX1 and 3 μg 
PANX11-89, or 8 μg PANX11-89, and pretreated for 10 min with 500 μM 
carbenoxolone (Cbx) or an equivalent volume of PBS; n = 4-8. b, Quantification 
of extracellular ATP release from PANX1-null mouse embryonic fibroblasts 
(PANX1 KO MEFs) transfected with 5 μg human full-length PANX1 or 5 μg  
human full-length PANX1 and 2.5 μg human PANX11-89; n = 7. c, Quantification 
of extracellular ATP release from PANX1 KO MEFs transfected with 5 μg human 
PANX11-89 or 5 μg vector control; n = 8. Error bars, s.e.m., ns, nonsignificant; *, P 
< 0.05; **, P < 0.01;  ***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 14. Augmentation of PANX1-mediated ATP release by PANX11-89 is 
independent of caspase activity.	 Quantification of PANX1-mediated ATP 
release from HEK293T cells transfected with 5 μg control vector, 5 μg wild-type 
PANX1 (DVVD), 2.5 μg wild-type PANX1 and 2.5 μg PANX11-89, 5 μg caspase 
resistant full-length PANX1 (AVVA), or 2.5 μg caspase resistant full-length 
PANX1 and 2.5 μg PANX11-89; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  
***, P < 0.001 by a one-tailed Student’s t-test.	
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Figure 15. The C-terminus of wild-type PANX1 channels is required for 
PANX11-89 to enhance PANX1-mediated ATP release. Quantification of ATP 
release from HEK293T cells transfected with 5 μg wild-type PANX1, 5 μg wild-
type PANX1 and 2.5 μg PANX11-89, 5 μg C-terminus-deleted PANX11-297 or 5 μg 
PANX11-297 and 2.5 μg PANX11-89; n = 8-12. Error bars, s.e.m., ns, nonsignificant; 
*, P < 0.05; **, P < 0.01;  ***, P < 0.001 by a one-tailed Student’s t-test. 
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PANX11-89. These findings reveal that PANX11-89 interacts with full-length 
PANX1 to augment ATP release through PANX1 channels.  
These results prompted the question of whether metastatic breast cancer 
cells express active PANX1 channels. Treatment of CN-LM1A and MDA-LM2 
cells with three established PANX1 inhibitors—probenecid (Prob)34,36, Cbx, or the  
more potent mimetic peptide 10Panx128,34,37 (Fig. 12)—significantly reduced 
extracellular ATP release (Fig. 16a), suggesting that highly metastatic cells 
mediate substantial ATP release through PANX1 channels. It was next asked 
whether the increased expression of PANX11-89 in metastatic breast cancer cells 
impacts PANX1 channel activity. CN-LM1A and MDA-LM2 sub-lines, which RNA-
seq revealed to express roughly 1.5-fold more PANX1 C268T than their parental 
lines, secreted nearly 5-fold more PANX1-mediated ATP than their parental lines 
(Fig. 16b). This increase in channel activity can not be attributed to greater 
expression of PANX1 in highly metastatic cells, as metastatic CN-LM1A and 
MDA-LM2 cells did not display increased total PANX1 mRNA levels relative to 
their parental lines (Fig. 17). These data suggest that PANX11-89 may nonlinearly 
augments PANX1-mediated ATP release. Moreover, expressing PANX11-89 in 
BT549, MDA-MB-468 and HCC1806 cells—three distinct human breast cancer 
cell lines harboring wild-type endogenous PANX1—was sufficient to significantly 
enhance PANX1-mediated ATP release (Fig. 18). These findings reveal PANX11-
89 to be an activator of PANX1 channels and implicate the N-terminal domain of 
PANX1 as a positive regulator of channel activation in metastatic breast cancer 
cells.      
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Figure 16. Highly metastatic breast cancer cells exhibit enhanced ATP 
release via PANX1 channels. a, Quantification of PANX1-mediated ATP 
release from MDA-LM2 (left panel) and CN-LM1A (right panel) sub-lines 
pretreated for 10 min with PBS, 2mM probenecid (Prob), 500 μM Cbx, or 100 μM 
10Panx1 peptide; n = 3-4. b, Time-course measurements of ATP release from 
MDA-MB-231 (left panel) and CN34 (right panel) parental cells and the MDA-
LM2 and CN-LM1A metastatic derivatives sub-lines pretreated with Cbx (500 μM) 
or PBS for 10 min; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 
0.001 by a one-tailed Student’s t-test. 
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Figure 17. Total PANX1 expression in in vivo selected metastatic breast 
cancer cells. CN34, CN-LM1A, MDA-MB-231 and MDA-LM2 total PANX1 
mRNA expression quantified by RNA-seq; FPKM values averaged over two 
rounds of RNA-seq for each cell line. Error bars, s.e.m. 
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Figure 18. PANX11-89 enhances PANX1 activity in metastatic breast cancer 
cells. Quantification of Cbx-sensitive ATP release from BT549, MDA-MB-468 
and HCC1806 metastatic breast cancer cells expressing PANX11-89 or a control 
vector; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 0.001 by a 
one-tailed Student’s t-test. 
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The role of PANX1 activation in metastatic progression was subsequently 
examined. It was first asked whether PANX1 channels are activated in vivo. To 
address this, MDA-LM2 cells expressing plasma membrane-anchored 
extracellular luciferase were treated with Cbx or vehicle, injected into the tail-
veins of mice, and the extracellular ATP release from cancer cells in the lung was 
quantified through bioluminescence imaging of the lungs. Consistent with 
PANX1-mediated ATP release in vivo, cancer cells entering the lung vasculature 
were found to release extracellular ATP that was attenuated upon 
pharmacological inhibition of PANX1 (Fig. 19). To determine if the early 
activation of PANX1 in the blood vessels of the lung is necessary for efficient 
metastasis, PANX1 channels were acutely blocked by preincubating CN-LM1A 
and MDA-LM2 cells with the 10Panx1 inhibitory peptide or its corresponding 
scrambled peptide and their metastatic activity was assessed through tail-vein 
lung colonization assays. This acute (30 min) inhibition of PANX1 significantly 
inhibited metastasis as evidenced by reductions in metastasis at early time-
points that persisted at 6-week endpoints (Fig. 20). PANX11-89 expression was 
also sufficient to promote metastasis in cancer cells expressing endogenous 
wild-type PANX1, as expressing the truncated mutant in MDA-MB-468 and 
HCC1806 cells led to a significant increase in metastatic dissemination in 
orthotopic (Fig. 21) and tail-vein  (Fig. 22) metastasis assays. These experiments 
also revealed the non-organ-specific pro-metastatic effect of PANX11-89, as cells 
expressing the mutation exhibited an enhanced capacity to spread systemically 
and colonize distant organs such as the lung, liver and bone (Fig. 22). Consistent  
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Figure 19. Breast cancer cell PANX1 channels are active soon after entry 
into the lung vasculature. Quantitative bioluminescence imaging of 
extracellular ATP release by cancer cells in the lung vasculature 5 min after tail-
vein injection of 1 × 105 MDA-LM2 cells expressing plasma membrane-anchored 
extracellular luciferase (MDA-LM2-pmeLUC). MDA-LM2-pmeLUC cells were 
pretreated for 10 min with either Cbx (500 μM) or PBS prior to injection into 
FVB/NJ mice; n = 5-7. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 0.001 
by a one-tailed Student’s t-test. 
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Figure 20. PANX1 activity promotes metastatic lung colonization. a, 
Quantitative bioluminescence imaging of lung metastasis after the injection of 1 × 
105 highly metastatic CN-LM1A breast cancer cells pretreated with 100 μM 
10Panx1 or scrambled peptide, into NOD scid (NS) mice; n = 6-7. b, Day 42 
quantification of metastatic foci (left) and representative lung images (right) from 
H&E stained lungs of mice injected with CN-LM1A cells pretreated with 10Panx1 
or scrambled peptide; n = 3. c, Quantitative bioluminescence imaging of lung 
metastasis after the injection of 4 × 104 MDA-LM2 (right panel) breast cancer 
cells pretreated with 100 μM 10Panx1 or scrambled peptide, into NOD scid (NS) 
mice; n = 5. d, Day 42 quantification of metastatic foci (left) and representative 
lung images (right) from H&E stained lungs of mice injected with MDA-LM2 cells 
pretreated with 10Panx1 or scrambled peptide. Error bars, s.e.m., *, P < 0.05; **, 
P < 0.01;  ***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 21. PANX11-89 promotes spontaneous metastatic dissemination and 
colonization. a, The numbers of vimentin positive breast cancer cells in the lung 
were counted one week after the extraction of size-matched mammary fat pad 
primary tumours generated by the orthotopic injection of 2.5× 105 MDA-MB-468 
cells expressing PANX11-89 or control vector into NOD scid gamma (NSG) mice; 
n = 3-5. b, Quantitative bioluminescence imaging of systemic metastasis one 
week after the extraction of size-matched mammary fat pad tumours generated 
by the orthotopic injection of 5 × 105 HCC1806 breast cancer cells expressing 
PANX11-89 or control vector into NSG mice; n = 7-9. Error bars, s.e.m., *, P < 
0.05; **, P < 0.01;  ***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 22. The pro-metastatic effect of PANX11-89 is non-organ-specific. 
Quantitative bioluminescence imaging of systemic metastasis after the tail-vein 
injection of 1 × 106 MDA-MB-468 breast cancer cells, expressing PANX11-89 or 
control vector, into NSG mice (left). Ex vivo bioluminescence imaging of 
metastatic target organs (lung, liver and bone) 14 days after tain-vein injection of 
MDA-MB-468 cells (right). Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 
0.001 by a one-tailed Student’s t-test. 
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Figure 23. PANX1 C268T is detected in metastatic breast cancers tropic for 
bone and brain. Sanger sequencing traces from the cDNA of MDA-MB-231 and 
CN34 parental cell lines as well as the MDA-MB-231 bone-tropic sub-line 1833, 
the MDA-MB-231 brain-tropic sub-line 2287 and the CN34 brain-tropic sub-line 
BrM.  
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with this, the PANX1 C268T mutation was detected in MDA-MB-231 sub-lines 
tropic for bone and brain as well as a CN34 sub-line tropic for brain (Fig. 23).  
Because purinergic signaling at the plasma membrane plays a role in 
many cellular processes30, it was hypothesized that augmented ATP release 
through mutant PANX1 channels could be responsible for the metastasis-
enhancing effect of PANX11-89. To address this, CD39, a plasma membrane- 
anchored extracellular ATP hydrolase, was expressed in CN-LM1A cells. The 
ability for these cells to metastasize to the lungs was then tested. CD39 
expression, which effectively depleted the levels of extracellular ATP (Fig. 24), 
significantly reduced the metastatic lung signal at early (Fig. 25c) and late (Fig. 
25a) time-points, and substantially reduced the number of metastatic foci in the 
lungs (Fig. 25b).  
Because the metastatic effects of PANX1 inhibition, PANX11-89 expression and 
extracellular ATP depletion were consistently significant within 24 hrs of cancer 
cells being tail-vein injected, the role of PANX1 channels within this time frame 
was tested. To confirm that PANX1 channel inhibition blunts early metastatic 
dissemination, tail-vein injections of CN-LM1A and MDA-LM2 metastatic cells 
pretreated with 10Panx1 were performed and lung bioluminescence was 
quantified daily, over three days. Consistent with PANX1 channels functioning to 
promote early metastatic dissemination, inhibition of PANX1 led to a significant 
(2-fold) decrease in lung bioluminescence as early as day one (Fig. 26a), as well 
as a reduction in the number of disseminated breast cancer cells detected 
histologically at day three (Fig. 26b).  
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Figure 24. CD39 effectively depletes extracellular ATP. Quantification of 
extracellular ATP release from CN-LM1A cells expressing the extracellular ATP 
hydrolase CD39 or control vector; n = 8. Error bars, s.e.m., ***, P < 0.001 by a 
one-tailed Student’s t-test. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 
0.001 by a one-tailed Student’s t-test. 
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Figure 25. Extracellular ATP promotes breast cancer metastasis to the 
lung.	 a. Quantitative bioluminescence imaging of lung metastasis after tail-vein 
injection of 1 × 106 metastatic CN-LM1A cells, expressing CD39 or control vector, 
into NS mice; n = 5-6. b, Lungs from day 42 were extracted, H&E stained, and 
the numbers of metastatic foci were quantified; n = 10-12. c, Daily quantitative 
imaging of lung bioluminescence for three days subsequent to the injection of 1 × 
105 CN-LM1A breast cancer cells expressing CD39 or control vector, into NS 
mice; n = 5-6.  Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 0.001 by a 
one-tailed Student’s t-test. 
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Figure 26. PANX1 channel activity promotes metastatic dissemination 
within days of cancer cell entry into the blood stream. a, Daily quantitative 
imaging plot of lung bioluminescence subsequent to the injection of 1 × 105 
metastatic CN-LM1A (left panel) or 4 × 104 MDA-LM2 (right panel) breast cancer 
cells pre-treated (30 min) with 100 μM 10Panx1 or scrambled peptides, into NS 
mice; n = 7. b, Lungs from mice were extracted at day 3, sectioned and stained 
for vimentin and the numbers of vimentin-positive cancer cells were quantified; n 
= 7. Error bars, s.e.m., *, P < 0.05; **, P < 0.01;  ***, P < 0.001 by a one-tailed 
Student’s t-test. 
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Figure 27. Molecular PANX1 inhibition does not suppress breast cancer cell 
proliferation. Quantification of proliferation over 5 days for CN-LM1A and MDA-
LM2 cells over-expressing the autoinhibitory C-terminal domain of PANX1 or 
control vector; n = 4. Error bars, s.e.m. 
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Figure 28. Peptidergic PANX1 inhibition has no effect on early proliferation. 
Quantification of 24 hour cell survival for CN-LM1A and MDA-LM2 cells 
pretreated for 15 min with 100μM 10Panx1 or scrambled peptide; n = 7-8. Error 
bars, s.e.m. 
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Figure 29. PANX1 activity is not required for invasion. Quantification of 24 
hour invasion for CN-LM1A and MDA-LM2 cells in the presence of 100μM 
10Panx1 or scrambled peptide; n = 4. Error bars, s.e.m. 
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Figure 30. PANX1 activity is not required for transendothelial migration. 
Quantification of 24 hour trans-endothelial migration for MDA-LM2 cells in the 
presence of 100 μM 10Panx1 or scrambled peptide; n = 4. Error bars, s.e.m. 
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Figure 31. PANX1 activity is not required for anchorage-independent cell 
survival. Quantification of 36 hour anchorage-independent cancer cell survival 
for CN-LM1A cells in the presence of 100 μM 10Panx1 or scrambled peptide; n = 
4. Error bars, s.e.m. 
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The acute impact of PANX1 channel inhibition on cancer-cell lung 
bioluminescence at 24 hrs suggested a block in metastatic progression while 
cells were in the vasculature. In support of this, PANX1 blockade did not inhibit 
proliferation, invasion, transendothelial migration or anchorage-independent cell 
survival capacity (Figs. 27-31). To assess cancer-cell fate in the lung vasculature, 
CN-LM1A and MDA-LM2 metastatic cells preincubated with 10Panx1 or 
scrambled peptides were injected into the tail-vein of mice and in vivo caspase 
activity was quantified using a luciferase-based reporter. In support of enhanced 
intravascular cell death, in vivo caspase activity was significantly augmented 
upon PANX1 inhibition at early time-points (3 and 6 hrs) post-injection (Fig. 32)—
well before monocyte recruitment (24 hrs)38 or extravasation (48 hrs)18,38. The 
function of PANX11-89 in intravascular metastatic cell survival was then tested. 
Expression of PANX11-89 in BT549 and MDA-MB-468 cells led to significant (2-3 
fold) increases in cancer-cell lung bioluminescence 18 hrs after injection (Fig. 
33a) and significant decreases in in vivo caspase activity 3 hrs and 6 hrs after 
injection (Fig. 33b). These data establish a role for PANX11-89 in the suppression 
of intravascular cell death through its enhancement of PANX1 channel activity 
and reveal PANX1 as a driver of metastatic breast cancer cell dissemination.  
Confocal microscopy revealed that, at the time when PANX1 activity was 
found to mediate survival (3 hrs post-injection), cancer cells were confined within 
the pulmonary vasculature and many had become morphologically elongated in 
small blood vessels (Fig. 34). Consistent with the quantitative in vivo caspase  
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Figure 32. PANX1 channel inhibition increases caspase-mediated 
intravascular cancer cell death. In vivo quantification of luciferase-based 
caspase-3/7 activity at 3 hr and 6 hr after tail-vein injection of 1 × 105 CN-LM1A 
(left panel) or 4 × 104 MDA-LM2 (right panel) breast cancer cells, pre-treated with 
100 μM 10Panx1 or scrambled peptide, into NS mice; n = 5. Error bars, s.e.m., *, 
P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 33. PANX11-89 promotes the intravascular survival of breast cancer 
cells. a, Quantitative imaging of lung bioluminescence 18 hrs post tail-vein 
injection of 1 × 106 BT549 (left panel) and 1 × 106 MDA-MB-468 (right panel) 
breast cancer cells, expressing PANX11-89 or a control vector, into NSG mice; n = 
6. b, In vivo quantification of luciferase-based caspase-3/7 activity at 3 hr and 6 
hr post tail-vein injection of 1 × 106 BT549 (left panel) or 1 × 106 MDA-MB-468 
(right panel) breast cancer cells, expressing either PANX11-89 or a control vector, 
into NS mice; n = 4−5. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 
by a one-tailed Student’s t-test. 
a 
b	
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Figure 34. Confocal microscopy of cancer cells in the lung 
microvasculature. Representative images of mouse lungs stained for cancer 
cells and blood vessels (green and red, respectively, top panel), blood vessels 
(black, middle panel ) or cleaved caspase-3 (white, bottom panel) 3 hrs after tail-
vein injection of 1 × 105 CN-LM1A cells pre-treated with 100 μM 10Panx1. Arrows 
indicate endothelium. 
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measurements, a number of these intravascular cancer cells displayed activated 
caspase immunoreactivity (Fig. 34). Of the many mechanisms responsible for the 
inefficiency of metastasis, intravascular death is responsible for the loss of up to 
>90% of the cancer cells entering the microvasculature of a secondary organ39-42. 
Because PANX1 is a mechanosensitive channel that opens during plasma 
membrane stretch24-27 and caspase-positive breast cancer cells were often 
elongated in the small lung vessels soon after injection (Fig. 34), it was 
hypothesized that PANX1 activation during cancer cell deformation in the 
vasculature might underlie its observed role in early cancer-cell survival. To test 
this, it was first asked whether PANX1 channels could be mechanically activated 
in metastatic breast cancer cells. Hypotonic cell swelling—an established 
perturbation that imparts plasma membrane stretch in a well-controlled manner25-
27,43,44—significantly increased the amplitude of PANX1-mediated ATP release in 
CN-LM1A and MDA-LM2 breast cancer cells (Fig. 35). To test the role of PANX1 
activity in promoting survival during membrane stretch, CN-LM1A and MDA-LM2 
cells were hypotonically stretched in the presence of 10Panx1 or scrambled 
peptides. The number of viable cancer cells remaining after incubation in 
hypotonic solution was significantly reduced when cells were subjected to 
PANX1 channel inhibition (Fig. 36). Importantly, cell viability was fully rescued in 
the PANX1-inhibited cells through the addition of extracellular ATP (Fig. 36), 
suggesting that ATP signaling at the cell surface mediates the observed survival 
phenotype. Furthermore, CN-LM1A and MDA-LM2 cell viability was dramatically 
decreased upon exposure to hypotonic solution supplemented with suramin (Fig.  
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Figure 35. Plasma membrane stretch activates mechanosensitive PANX1 
channels in metastatic breast cancer cells. Quantification of PANX1-mediated 
Cbx-sensitive ATP release from CN-LM1A and MDA-LM2 cells during 5 min 
exposure to isotonic (100% PBS) or hypotonic (70% PBS) solution; n = 3−4. 
Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed 
Student’s t-test. 
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Figure 36. ATP-release from PANX1 channels promotes cell survival during 
plasma membrane stretch. Quantification of viable, trypan blue-negative, CN-
LM1A (left panel) and MDA-LM2 (right panel) cells after 1 hr incubation in 
extremely hypotonic (12.5% PBS) solution in the presence of scrambled peptide 
(100 μM), 10Panx1 peptide (100 μM) or 10Panx1 peptide (100 μM) and 100 μM 
ATP; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-
tailed Student’s t-test. 
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Figure 37. Purinergic signaling via P2y receptors promotes cell survival 
during plasma membrane stretch. Quantification of viable, trypan blue-
negative, CN-LM1A (left panel) and MDA-LM2 (right panel) cells after 15 min 
incubation in extremely hypotonic (12.5% PBS) solution in the presence of 
suramin (50 μM) or water vehicle; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 
0.01; ***, P < 0.001 by a one-tailed Student’s t-test. 
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37)—a broad-spectrum antagonist of ATP-binding P2y purinergic receptors 
(P2yRs)45. These data suggest that ATP release stimulated by plasma 
membrane stretch activates P2yRs that signal to protect cancer cells from lethal 
mechanical injury. Consistent with ATP being necessary for cancer cell survival 
in the vasculature, CN-LM1A and MDA-LM2 lung bioluminescence was 
significantly reduced 6 hrs after tail-vein co-injection of cells with apyrase, a 
potent extracellular ATP hydrolase (Fig. 38)28,46. These data reveal a role for 
extracellular ATP release through mechanosensitive PANX1 channels as a 
cancer-cell-autonomous survival signal during critical deformation of the plasma 
membrane.   
PANX11-89 expression was also found to promote cancer-cell survival 
during membrane stretch. CN-LM1A and MDA-LM2 sub-lines, in which display 
greater PANX11-89 expression and PANX1 activity relative to their parental lines, 
were significantly more resistant to lethal hypotonic stretch than their parental 
lines (Fig. 39). Moreover, expressing PANX11-89 in BT549 and MDA-MB-468 cells 
significantly enhanced the survival of these lines during hypotonic stretch (Fig. 3l). 
The addition of apyrase to PANX11-89-expressing cells in hypotonic solution 
completely abrogated the survival advantage afforded by PANX11-89 expression 
(Fig. 40), suggesting that extracellular ATP is responsible for this effect. These 
data reveal that PANX11-89−induced PANX1 channel activity enhances the 
efficiency of metastasis by promoting metastatic breast cancer cell survival 
during physical deformation. 
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Figure 38. Extracellular ATP is required for early cancer cell survival in the 
lung vasculature. a, Quantitative imaging of lung bioluminescence at 6 hrs post 
tail-vein injection of 1 × 105 CN-LM1A (left panel) or 4 × 104 MDA-LM2 (right 
panel) breast cancer cells pre-treated (30 min) and co-injected with apyrase 
(2U/ml) into FVB/NJ mice; n = 6. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, 
P < 0.001 by a one-tailed Student’s t-test. 
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Figure 39. Highly metastatic breast cancer sub-lines exhibit increased 
resistance to stretch-induced cell death. Quantification of viable, trypan blue-
negative, CN34, CN-LM1A, MDA-MB-231 and MDA-LM2 cells after 1 hr extreme 
hypotonic (12.5% PBS) stretch; n = 4. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; 
***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 40. Augmented PANX1-mediated ATP release by PANX11-89 promotes 
cell survival during plasma membrane stretch. Quantification of viable, trypan 
blue-negative BT549 (left panel) and MDA-MDA-468 (right panel) cells 
expressing PANX11-89 or a control vector after 1 hr extreme hypotonic (12.5% 
PBS) stretch in the presence of succinate buffer or apyrase (2U/ml); n = 4. Error 
bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student’s t-
test. 
 
 
 
 
 
 
 
	64
CHAPTER IV: THE CLINICAL SIGNIFICANCE OF ACTIVATED PANX1 
CHANNELS IN METASTASIS 
To determine if PANX1 mutations are relevant to human cancer 
progression, publically available cancer-sequencing datasets were analyzed (see 
methods). This search uncovered six additional PANX1-truncating mutations in 
cancers of the colon, lung and brain (Fig. 41 and Table 4). In addition to the 
truncating mutations, an in-frame deletion of lysine 91 was detected in a breast 
carcinoma, while missense mutations were found in eleven lung carcinomas, five 
colon carcinomas, two liver carcinomas, two endometrial carcinomas, as well as 
cancers of the breast, bladder, pancreas, esophagus, larynx, kidney and prostate 
(Table 4). Four of the PANX1 missense mutations predicted by PolyPhen-2 to be 
non-neutral were then tested for their effects on PANX1-mediated ATP release.  
Consistent with channel-activating functional roles, each of the four missense 
mutations significantly augmented PANX1-mediated ATP release relative to wild-
type PANX1 (Fig. 42). To determine if mutant PANX1 could promote metastasis 
by an epithelial cancer type other than breast cancer, PANX1 L47fs*18—a 
truncating mutation detected in a metastatic colon adenocarcinoma (Fig. 41)—
was expressed in WiDR and sw480 human colon cancer cell lines harboring wild-
type endogenous PANX1. The expression of L47fs*18 in both of these lines 
significantly enhanced PANX1-mediated ATP release (Fig. 43), hepatic 
dissemination at early time-points (Fig. 44), liver metastatic colonization upon 
portal-circulation injection of cancer cells (Fig. 45), as well as survival during 
membrane stretch (Fig. 46). PANX1 L47fs*18 also co-localized with full-length  
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Figure 41. The distribution of PANX1 mutations detected in patients’ 
primary tumors. Top panel, the distribution of PANX1 mutations detected in 
clinical tumours. Red: truncation; green: deletion; blue: substitution.      , bladder;      
, brain;      , breast;     , colon;      , endometrium;      , kidney;      , larynx;       , 
liver;      , lung;      , oesophagus;      , pancreas; and      , prostate. Bottom panel, 
schematics of the PANX1 domain fragments predicted to be generated by 
truncating mutations identified in cancers of the colon (L47fs*18 and C228*), lung 
(S182_splice and G401_splice), brain (G99* and S182_splice) and the 
recurrently enriched nonsense mutation in metastatic breast cancer cells (Q90*). 
Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed 
Student’s t-test. 
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Table 4. Frequencies of PANX1 mutations in patients’ primary tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Tissue Histology Unique mutated samples (NS/MS) Total samples Mutation frequency (%)
Larynx Squamous cell Ca 1 17 5.88
Lung Squamous cell Ca 4 179 2.23
Lung Adenocarcinoma 9 596 1.51
Breast (TCGA) HER2-enriched 1 58 1.72
Breast (TCGA) Basal-like 1 98 1.02
Colon Adenocarcinoma 7 498 1.40
Pancreas Ductal Ca 1 137 0.73
Prostate Carcinoma 1 319 0.31
Endometrium Endometrioid Carcinoma 2 258 0.78
Liver Hepatocellular Ca 2 72 2.78
Brain Neuroblastoma 2 362 0.55
Bladder Carcinoma 1 103 0.97
Esophagus Adenocarcinoma 1 161 0.62
Kidney Clear Cell Carcinoma 1 359 0.28
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Figure 42. The effect of clinically identified non-neutral missense mutations 
on PANX1-mediated ATP release. Quantification of Cbx-sensitive ATP release 
from HEK293T cells transfected with 5 μg wild-type PANX1 (dotted line), 2.5 μg 
wild-type PANX1 and 2.5 μg mutant PANX1, or 5 μg mutant PANX1; n = 3−4. c, 
Quantification of Cbx-sensitive ATP release from WiDR colon cancer cells 
expressing PANX1-L47fs18* or a control vector; n = 8. Error bars, s.e.m., *, P < 
0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 43. PANX1 L47fs*18 enhances PANX1-mediated ATP release from 
metastatic colon cancer cells. Quantification of Cbx-sensitive ATP release from 
sw480 (left panel) or WiDR (right panel) colon cancer cells expressing PANX1-
L47fs18* or a control vector; n = 8. b, Error bars, s.e.m., *, P < 0.05; **, P < 0.01; 
***, P < 0.001 by a one-tailed Student’s t-test. 
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Figure 44. PANX1 L47fs*18 promotes the early hepatic dissemination of 
cancer cells. Quantitative imaging of liver bioluminescence at one, two and four 
days after the intrasplenic injection of 5 × 105 sw480 (left panel) or WiDR (right 
panel) colon cancer cells, expressing PANX1 L47fs18* or a control vector, into 
NSG mice; n = 5. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a 
one-tailed Student’s t-test. 
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Figure 46. PANX1 L47fs*18 promotes cell survival during plasma 
membrane stretch. Quantification of viable, trypan blue-negative sw480 (left 
panel) and WiDR (right panel) colon cancer cells cells, expressing PANX11-89 or 
a control vector, after 2 hr extreme hypotonic (12.5% PBS) stretch; n = 4. Error 
bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student’s t-
test. 
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Figure 47. PANX1 L47fs*18 colocalizes with full-length PANX1. Confocal 
microscopy images of PANX1 KO MEFs expressing human PANX1-EGFP 
(green) and PANX1-L47fs*18-mRFP (red). Colocalization is shown by channel 
overlay (yellow).  
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PANX1 (Fig. 47), suggesting that this mutation, like PANX11-89, may also 
augment ATP release through interactions with full-length PANX1. These 
findings, as a whole, reveal a role for mutationally activated PANX1 channels in 
the survival and progression of multiple cancer types.  
The discovery that PANX1 channel-activating mutations could promote 
metastasis led to the question of whether patients’ cancers might also augment 
their ability to release ATP by upregulating PANX1 expression as they progress. 
In support of this possibility, PANX1 expression was significantly increased in 
high-grade breast cancers (Fig. 48), and patients whose primary breast, colon or 
lung tumors exhibited high PANX1 expression had significantly worse 
metastasis-free survival (Fig. 49). These data suggest that many cancers use 
increasing PANX1 expression in addition to mutational PANX1 activation to 
achieve the levels of ATP release optimal for metastasis. 
Finally, the effect of pharmacologically inhibiting open PANX1 channels in 
metastatic cells during metastatic progression was tested. CN-LM1A cells 
pretreated with Cbx, a PANX1 channel inhibitor approved for the treatment of 
gastroesophogeal reflux disease (GERD) in the UK, showed a 100-fold reduction 
in their ability to metastasize to the lungs (Fig. 50). To better assess the clinical 
potential of this therapy, mice were treated with two different Cbx regimens prior 
to introducing metastatic breast cancer cells into the circulation (Fig. 51). Seven 
days of Cbx treatment significantly inhibited (3-fold) the ability for MDA-LM2 cells 
to colonize the lungs (Fig. 52a-b). Importantly, this treatment was well tolerated  
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Figure 48. PANX1 expression in low- and high-grade breast cancer tumors. 
PANX1 transcript expression in Bloom-Richardson low- (I, II) and high-grade (III) 
breast cancer tumours from the expO (n = 252) and GSE5460 (n = 129) 
datasets. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-
tailed Student’s t-test.	
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Figure 49. Correlation of metastasis-free survival and PANX1 expression 
levels in primary tumors from breast, colon and lung cancer patients. 
Kaplan–Meier curves for breast cancer47 (n = 508), colon cancer GSE17536 (n = 
177) and lung cancer47 (n = 1404) datasets depicting metastasis-free survival of 
patients as a function of their primary tumours’ PANX1 expression status. An 
expression greater or lower than the mean for the entire population was 
classified as high or low PANX1 expression, respectively. P values are based on 
a Mantel–Cox log-rank test. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 
0.001 by a one-tailed Student’s t-test. 
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Figure 50. Pharmacological inhibition of PANX1 reduces lung metastasis. a, 
Quantitative bioluminescence imaging of lung metastasis after tail-vein injection 
of 1 × 105 CN-LM1A breast cancer cells pretreated for 30 min with Cbx (500 μM) 
or PBS vehicle into NS mice; n = 4-6. b, Day 35 quantification of metastatic foci 
(left) and representative lung images (right) from H&E stained lungs of mice 
injected with CN-LM1A cells pretreated with Cbx or PBS vehicle; n = 4-6. Error 
bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a one-tailed Student’s t-
test.  
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Figure 51. Therapeutic Cbx regimens tested in the study. Schematic 
depicting the two in vivo Cbx therapy regimens tested for pharmacological effect 
on breast cancer metastasis to the lung. 
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Figure 52. In vivo therapeutic inhibition of PANX1 channels with Cbx 
inhibits metastatic dissemination and lung colonization. a, Quantitative 
bioluminescence imaging of lung metastasis after tail-vein injection of 5 × 104 
MDA-LM2 breast cancer cells into NS mice pretreated daily with 25 mg/kg i.p. 
Cbx or an equivalent volume of PBS for six days and with 100 mg/kg i.v. Cbx or 
an equivalent volume of PBS 30 min prior to cancer cell injection; n = 4-6. b, 
Lungs were extracted at day 14, H&E stained, and the number of metastatic foci 
were quantified; n = 4. c, Quantitative bioluminescence imaging of breast cancer 
cells in the lung 24 hrs after tail-vein injection of 1 × 105 CN-LM1A breast cancer 
cells into NS mice pretreated with 25 mg/kg i.p. Cbx or an equivalent volume of 
PBS 19 and 2 hours prior to cancer cell injection; n = 10. d, Lungs were extracted 
at 24 hrs, sectioned and stained for vimentin and the number of vimentin-positive 
cancer cells were quantified; n = 7-8. e, Quantitative bioluminescence imaging of 
the lungs at 4 weeks after tail-vein injection of 1 × 105 CN-LM1A breast cancer 
cells into NS mice pretreated with 25 mg/kg i.p. Cbx or an equivalent volume of 
PBS 19 and 2 hours prior to cancer cell injection; n = 9-10.  f, Lungs were 
extracted at week 4, H&E stained, and the numbers of metastatic foci were 
quantified; n = 9-10. Error bars, s.e.m., *, P < 0.05; **, P < 0.01; ***, P < 0.001 by 
a one-tailed Student’s t-test. 
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Figure 53. In vivo Cbx therapy does not affect mouse body weight. Mouse 
body weight before and after daily i.p. injections of Cbx (25 mg/kg) or an 
equivalent volume of PBS vehicle for seven days; n = 4-6. Error bars, s.e.m., ns, 
nonsignificant by a one-tailed Student’s t-test.  
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and did not impact body weight (Fig. 53). Strikingly, reducing this treatment to 
two	 doses of Cbx within 24 hrs of cancer cell injection significantly reduced the 
number of CN-LM1A cells in the lungs at as early as 24 hrs (Fig. 52c-d) as well 
as lung metastatic colonization at four weeks (Fig. 50e-f). 
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CHAPTER V: SUMMARY 
This work identifies PANX1 mutations in multiple cancers as activators of 
PANX1 channel activity and drivers of metastasis in epithelial cancers such as 
breast and colon carcinomas. A working model is proposed whereby the 
mutational augmentation of ATP release via mechanosensitive PANX1 channels 
cell-autonomously promotes cancer cell survival in the setting of microvascular-
induced physical stress—an important barrier to metastatic progression (Fig. 54). 
The data presented suggest that ATP exerts this effect through purinergic 
receptors on the cell surface, which have been previously implicated in survival 
signaling during mechanical stress46. The integrated approach to identifying and 
functionally testing putative metastasis-promoting genetic variants developed and 
employed in this study also identified PANX1 as a potential therapeutic target 
whose inhibition may reduce the development of metastasis. In the future, follow 
up studies investigating the specific molecular and structural mechanisms by 
which nonsense and missense mutations in PANX1 cause enhanced ATP 
release through activated PANX1 channels as well as studies testing the 
feasibility of targeting active PANX1 channels for the prevention of metastasis in 
humans, should be performed. 
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Figure 54. The working model: increased PANX1 channel activity enables 
intravascular metastatic cell survival. Proposed working model in which ATP 
released from stretch-activated PANX1 channels acts to suppress cancer cell 
death during mechanical stress in the microvasculature. The increased levels of 
PANX1 channel activity necessary for optimal metastatic efficiency may be 
achieved through mutational activation or enhanced gene expression. 
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CHAPTER VI: DISCUSSION 
The potential underestimation of PANX1-mutation frequency in cancer—
The identification of a recurrent mutation that promotes metastasis independent 
from cell proliferation raises questions about the rationale behind focusing the 
efforts of current cancer sequencing studies on uncovering those mutations that 
are most frequently detected in bulk tumors. Molecular blockade of PANX1 ATP-
release channels in MDA-LM2 cells resulted in accelerated cell proliferation (Fig. 
27), suggesting that mutations increasing the activity of these channels, while 
promoting the ability for a cell to survive vascular dissemination, might be 
selected against and as such result in only a small fraction of cells in the primary 
tumor harboring such mutations. The proliferative disadvantage of such PANX1-
mutant subclones would then allow the other, less metastatic, subclones to 
comprise the majority of a tumor. With our current next-generation tumor 
sequencing technologies—recently estimated to miss up to 37% of lower 
frequency mutations5,21—the frequencies at which such metastatic driver 
mutations are detected by the sequencing of bulk tumors are likely to be low. 
Further contributing to this problem is the contamination of tumor tissue with 
neighboring and intermingled non-cancerous stroma22. Until tumor preparation 
and sequencing technologies improve, in vivo selection can provide utility in 
allowing for the isolation and detection of low frequency mutations that 
specifically function to drive metastasis. 
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The molecular mechanisms of mutational PANX1 activation—Taken 
together, the results of this study show that, when expressed with full-length 
PANX1, a truncated version of the PANX1 protein consisting of only the first 89 
amino acids of the 426 amino acid protein (PANX11-89) (Fig. 8), interacts with full-
length PANX1 (Fig. 10) and increases the release of ATP mediated though 
PANX1 channels (Fig. 13). In metastatic breast cancer cells, this channel is 
mechanically activated by membrane stretch (Fig. 35). This increase in PANX1-
mediated extracellular ATP release was found to promote the survival of 
metastatic cells in the vasculature of the lung (Figs. 32 and 33) at a time when 
they have become physically deformed (Fig. 34). An interesting question that 
arises from these results is how, in molecular and structural terms, can an 89-
amino acid channel fragment cause increased activity of ATP-release channels? 
 While the most definitive answers to this question will require future 
crystolographic experimentation, evidence from this study provides some 
direction. Confocoal microscopy showed distinct co-localization of wild-type  
PANX1 and mutant PANX11-89 at the plasma membrane (Fig. 9), suggesting that 
1) despite truncation, PANX11-89 can effectively colocalize to the plasma 
membrane when co-expressed with wild-type PANX1 and, 2) interactions formed 
between PANX11-89 and wild-type PANX1 channels do occur at the cell surface. 
By crosslinking proteins in cultured cells before lysing them, the 
immunoprecipitation of PANX11-89 showed that mutant and wild-type PANX1 form 
a multimeric complex (Fig. 10). This crosslinked complex migrated at a molecular 
weight higher than would be expected if only one protein of each form were in 
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complex, suggesting that mutant PANX11-89 is integrated into a hetero-multimeric 
complex with PANX1. ATP-release studies indicated that the C-terminus of full-
length PANX1 is required for the PANX11-89-mediated enhancement of channel 
activity (Fig. 15). This observation suggests that the association between 
PANX11-89 and wild-type PANX1 may cause a conformational change in the 
structure of the PANX1 channel that relaxes the steric impedance of the pore by 
the autoinhibitory tail35.  
There are two possible models that may explain how PANX11-89 functions 
(Fig. 55). In the first model, PANX11-89 interacts with the normal PANX1 channel 
formed by six wild-type PANX1 subunits. PANX11-89 could either be anchored to 
the plasma membrane via its transmembrane domain (TM1) in proximity to the 
channel or it could remain completely cytoplasmic. (Fig. 55) Anchored to the 
membrane or not, it is likely that the mutant, resembling the N-terminal pore-
forming domain of the PANX1 channel48, functions as a decoy for the auto-
inhibitory C-terminus that normally interacts with TM1 to block the pore35. In the 
second model, PANX11-89 substitutes for one or more of the full-length PANX1 
subunits forming the channel (Fig 55). The observed increase in ATP-release 
might then be explained by a change in either the size of the pore or the 
mechanical gating of the channel. If this model holds true, then a mutant channel, 
with new molecular and physical properties, would emerge. To gain insight into 
which model is correct, one could test PANX1-mediated ATP release in the 
presence of increasing concentrations of the 10Panx1 peptide. If the PANX11-89 
	87
fragment replaces wild-type PANX1 to form a new channel, the response to the 
inhibitory peptide mimetic would be expected to be altered.  
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Figure 55. Hypothetical models of PANX11-89-mediated augmentation of 
PANX1 channel activity. See text for discussion. 
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Solving the question of how PANX11-89 mediates enhancement of ATP 
release through PANX1 channels should be of interest to many seemingly 
unrelated fields. Channel structural biologists and electrophysiologists may gain 
insight into the gating mechanisms of mechanosensitive channels in human 
cells—a largely unresolved area of research. Those in the field of membrane 
biophysics may benefit from a deeper understanding of the mechanisms bridging 
mechanical stress on the cell membrane and the pathways that translate these 
forces into molecular signals. And cancer biologists may begin to look for more 
specific molecules that can inhibit these mutant channels for the prevention of 
metastatic dissemination and may also be motivated to look for other molecular 
mediators of cellular deformation. 
 
The physical properties of metastatic cells—Observations that a large 
fraction of cancer cells perish upon arriving in the microvasculature of a 
secondary organ were first made over two decades ago39. While a bottleneck to 
metastatic colonization of this magnitude would seem to be of great interest to 
cancer biologists, relatively little effort has been given to furthering our 
understanding of the mechanisms that allow one cell to survive microvascular 
deformation when many others do not. An unbiased screen for mutations that 
promote metastasis has highlighted the importance of microvascular cell death 
as an impediment to metastatic colonization and has revealed the first molecular 
basis for cancer survival during lethal stretch. Investigations into other molecular 
regulators of survival during physical stress should be vigorously pursued.  
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A number of experiments could be performed to search for additional 
regulators of survival during deformation.  One method would be to inject cancer 
cells into the vasculature of mice, harvest the blood and lungs shortly after (on 
the order of hours), collect and expand the surviving cancer cells, and continue 
repeating the process until highly deformable metastatic cancer cells have been 
selected. One could then compare the abilities of the parental cells and the 
resulting highly deformable sub-lines to stretch in vivo and in vitro. If these sub-
lines prove to be more metastatic, any genetic changes (transcriptional, 
mutational, epigenetic, or otherwise) recurrently present in the deformable sub-
lines could be investigated. To improve the chance of identifying important 
regulators of cell survival during deformation, in vitro selection of deformable 
cells could be performed in parallel. Current methods for stretching cells in vitro 
include placing cells in hypotonic solution, running cells through a microfluidics 
device or applying physical force with a mechanical cell-stretching device. 
Looking for genetic alterations found by both in vivo and in vitro stretch selection 
methods should allow investigators to filter out many nonfunctional passenger 
genetic changes. To improve even further on the methods for identifying 
regulators of deformation that promote metastasis, the genetic changes identified 
by stretch selection could be compared to the genetic changes seen upon in vivo 
metastatic selection, as any important mediators of deformation that function to 
improve metastatic efficiency should be enriched under both selective processes. 
Identifying additional molecular regulators of survival during microvascular 
metastatic cell deformation may implicate new signaling pathways that could then 
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be targeted for the prevention of metastatic dissemination. Furthermore, a more 
detailed understanding of the physical characteristics of highly deformable cells 
may lead to the development of devices that could be surgically implanted into 
the vasculature of patients diagnosed with an aggressive primary tumor to 
specifically destroy cancer cells without disrupting erythrocytes, megakaryocytes, 
immune cells or other vital circulating factors.  
 
The therapeutic role for targeting cancer dissemination—The discovery of 
activating mutations in PANX1, a plasma membrane channel that promotes the 
efficiency of metastatic dissemination, has revealed a potential therapeutic target 
for the prevention of metastasis. In vivo inhibition of this channel through the 
treatment of mice with carbenoxolone (Cbx), a drug approved in the UK for the 
treatment of gastroesophageal reflux disease (GERD), was shown to significantly 
decrease both metastatic dissemination at 24 hrs and metastatic lung 
colonization (Fig. 52). These data suggest that inhibiting PANX1 channels with 
Cbx therapy in patients diagnosed with primary tumors of known or unknown 
metastatic capabilities may hold potential for reducing metastatic burden. 
However, before implementing clinical trials testing the efficacy of Cbx therapy in 
such patients, it must be determined whether PANX1 inhibition effects the 
proliferation of cancer cells. Because the molecular inhibition of PANX1 channels 
in MDA-LM2 cells led to their accelerated proliferation, in vivo experiments 
whereby mice with established tumors are treated with Cbx and evaluated for 
tumor growth must be performed. If the results of these experiments show 
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unaltered, or even reduced, tumor growth, then serious consideration to initiating 
the design and implementation of clinical trials should be given.  
If clinical trails do proceed and are shown to be effective, the future of 
targeting PANX1 may lie in resolving the structure of the open channel. 
Understanding the architecture of the pore and surrounding extracellular domains 
of PANX1 may suggest optimal targeting sites for the design of more specific and 
effective inhibitors.  
 
Other nSNVs enriched during breast cancer metastasis to the lung—This 
study identified five recurrent nSNVs significantly enriched during breast cancer 
metastasis to the lung that were predicted to cause non-neutral alterations in the 
proteins they encode (Table 2). Four of these mutations were missense 
substitutions and one was a nonsense truncation. This study revealed the 
nonsense mutation, PANX1 C268T, to be a promoter of microvascular cancer 
cell survival during metastatic dissemination. It will be important for future 
investigations to test whether any of the four missense mutations also function to 
promote metastasis. The genes bearing the missense mutations included the 
mitochondrial ribosome-binding factor RBFA, the transcription factor REST, the 
adherens junction regulatory factor KRIT1 and the zinc-finger-containing gene 
ZSWIM6. The potential functions of these mutations are discussed below.  
RBFA encodes ribosome binding factor A, a largely uncharacterized 
human protein that has been suggested to regulate and promote the late 
maturation of the 28S small ribosomal subunit (SSU) in the mitochondria49,50. 
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Inferences made by looking at 1) RbfA, the more thoroughly studied bacterial 
RBFA homologue, 2) the position of the RBFA G773T mutation in the RBFA 
protein (G258V), and 3) the function of mitochondrial proteins in general, suggest 
a possible role for this mutation in promoting metastasis. In bacteria, RbfA binds 
the SSU and plays a role in processing of the 16S rRNA precursor component of 
the SSU during late ribosome biosynthesis50,51. The release of RbfA from this 
subunit by the GTPase RsgA is required for the assembly of the bacterial 
ribosome50. Defects in RbfA release lead to growth defects that can be reversed 
by gain-of-function mutations in RbfA that result in the spontaneous release of 
RbfA from the SSU50. The location of the G258V mutation in the RBFA protein 
also provides a clue into its potential function. Glycine 258 is a highly conserved 
RBFA glycine that lies in the center of the GatB domain near the C-terminus of 
the RBFA. In the GatB protein, this domain interacts with tRNAs to transamidate 
Glu-tRNA to Gln-tRNA. Futhermore, structural studies have shown that RbfA 
binding to the SSU displaces a portion of the 16S rRNA involved in mRNA 
decoding and tRNA interactions51. It is possible that the GatB domain in human 
RBFA is responsible for interacting with rRNA during 28S SSU maturation and 
that a mutation in this domain might act to interfere with ribosomal maturation.  
The relationship between mitochondria biology and cancer is also quite 
well established. For many years it has been known that cancer cells exhibit 
increased aerobic glycolysis—a phenomenon known as “the Warburg effect”—
that makes the contribution of mitochondrial oxidative phosphorylation to total 
cellular energy production less significant52. Additionally, mitochondrial protein 
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alterations have also been implicated in promoting tumor cell metastasis through 
the generation of reactive oxygen species53.  Based on this information, a 
putative model for the enhancement of metastasis by RBFA G258V can be 
proposed. If functional, the RBFA G258V mutation would likely interfere with 
mitochondrial protein translation. A mutation causing RBFA to resist removal 
from the SSU would result in reduced expression of those genes translated in the 
mitochondria, the majority of which are members of the protein complexes that 
comprise the electron transport chain54. Faulty ribosome assembly caused by 
RBFA G258V mutations that instead promote the premature spontaneous 
release of RBFA from the SSU would also be likely to result in improper 
ribosome maturation with resultant defects in mitochondrial protein translation. 
Though there is much evidence linking metabolic defects to cancer progression, 
the specific effect of RBFA G258V on metastasis would require further focused 
investigation. 
Krev Interaction Trapped Protein 1 (KRIT1) functions in the regulation of 
cell-to-cell junctions between endothelial cells lining the blood vessel lumen55. 
The importance of normal KRIT1 function in maintaining stable endothelial 
junctions in humans has been validated by multiple studies identifying KRIT1 
mutations as the cause of cerebral cavernous malformations56-65. Additionally, 
deletion of KRIT1 in zebrafish led to the development of multiple vascular 
phenotypes, such as vessel dilation and thinning of vessel walls66. More recently, 
KRIT1 was shown to be a negative regulator of β-catenin signaling required for 
the stabilization of interactions between epithelial cells67. The junction-stabilizing 
	95
effects of KRIT1 are mediated by the binding of KRIT1 by the Rap1a GTPase68. 
The loss of KRIT1 at cell junctions results in increased β-catenin nuclear 
localization and transcriptional activity67. The KRIT1 S701N mutation resides in a 
highly conserved serine residue within the C-terminal KRIT1 band 
4.1/Ezrin/Radixin/Moesin (FERM) domain, that regulates KRIT1’s interaction with 
Rap1a as well as its localization to VE-cadherin-based adherens junctions55. This 
evidence suggests that a mutation in the KRIT1 FERM domain of metastatic cells 
could result in decreased cell adhesion and upregulated β-catenin signaling, both 
of which have been strongly implicated in promoting cancer metastasis69,70. To 
test this hypothesis, one could overexpress wild-type or mutant KRIT1 in the 
context of endogenous KRIT1 knockdown in metastatic cells and test their ability 
to metastasize in vivo. If these studies show that the expression of wild-type 
KRIT1 suppresses metastasis relative to KRIT1 S701N, investigations into the 
mutation’s effect on Rap1a binding and β-catenin signaling should naturally 
follow.  
RE1-silencing transcription factor (REST) functions as a repressor of 
neuron-specific genes in non-neural tissues and immature neurons71. REST has 
been shown to act as both a suppressor and promoter of tumor formation72,73. In 
breast cancer patients specifically, the loss of REST expression has been shown 
to result in a significantly worse prognosis and earlier disease recurrence74. The 
REST D941H mutation lies at the C-terminus of the REST protein. Interestingly, 
this mutation is positioned near a C-terminal zinc-finger domain known to bind to 
the co-repressor CoREST75 and to be sufficient for repressing neuronal 
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transcription 76. Based on this evidence, the REST D941H mutation could 
interfere with the interaction between REST and its C-terminal-binding co-
repressors to induce the expression of a certain set of neuronal genes that 
promote the de-differentiation and metastatic capability of epithelial breast cancer 
cells. This mutation should be investigated through in vivo metastasis assays in a 
manner similar to that described above for the testing of the KRIT1 mutation. If 
this mutation proves to be functional in metastasis, it would be interesting to then 
look at the gene signatures induced by REST D941H expression relative to wild-
type REST expression. 
ZSWIM6 is an uncharacterized zinc-finger-containing protein of 1215 
amino acids with no identifiable conserved domains. The ZSWIM6 V636M 
mutation lies near the center of this protein. By studying the role of wild-type 
ZSWIM6 and ZSWIM6 V636M in metastasis, important insight into its normal 
function could also be acquired.  
 
Studying putative metastasis mutations in the future—The recent 
development of new technologies for the study of nucleotide substitutions in 
human genes will certainly benefit those interested in testing putative metastasis-
promoting mutations. While overexpression and knockdown studies have 
become the mainstay of studying the function of protein coding mutations, they 
are not without significant drawbacks. Unless the function of a missense mutation 
is very simplistic, the overexpression of wild-type and mutant proteins to 
supraphysiological levels has the propensity to either create artificial phenotypes 
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or mask real effects. Similarly, the knockdown of genes using shRNA or siRNA 
can result in ineffective protein reduction. To overcome these challenges, those 
studying cancer genetics will likely adopt genome-editing techniques that 
significantly increase the efficiency of targeted gene modifications historically 
performed by homologous recombination.  
Zinc-finger nucleases (ZNFs), transcription activator-like effector 
nucleases (TALENs) are rapidly advancing systems increasingly utilized for 
targeted genomic editing in many cell types. The general mechanism by which 
these systems act to modify specific sequences in the genome is by recognizing 
and cleaving a desired endogenous DNA site to form double strand breaks 
(DSBs) that induce high frequency homology-directed repair (HDR)77. By 
simultaneously providing a plasmid of donor DNA containing the desired genomic 
alteration sequence flanked by DNA homologous to the site of the DSB, the 
desired edits can be incorporated into the native genome through HDR. These 
systems differ in the way they recognize target DNA sequences and, by 
extension, in which sequences they can be used to edit. While zinc-finger 
proteins can theoretically target any desired sequence, the DNA recognition 
sequences of TALENs are most efficient when they start with a thymine (T) 
nucleotide77.  
The clustered regularly interspaced short palindromic repeats (CRISPR) 
system is the most recent genome-editing method to emerge and is currently the 
most constrained in the sequences it can be used to edit78. The CRISPER 
system acts as a site-specific DNA endonuclease that is used to perform RNA-
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guided genome editing in human cells77,78. While it shows much promise, fairly 
strict target sequence requirements of the CRISPER/Cas system make it the 
most constrained of the three systems. However, since it is the most affordable 
method available for targeted genome editing, CRISPER will likely become 
rapidly more versatile in time. 
By adding or removing a potentially functional mutation from the genome 
of cancer cells, these molecular tools will overcome the drawbacks of 
overexpression and knockdown highlighted above. As the efficiency of editing 
improves over time, these systems will likely become the gold standard for 
testing the roles of putative mutations in many diseases—perhaps most 
predominantly those implicated in cancer initiation and metastasis. As our 
understanding of the mutational drivers of cancer progression advances, more 
effective targeted therapies can be developed. 
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CHAPTER VII: MATERIALS AND METHODS 
Cell culture—BT549 and MDA-MB-468 cells were a generous gift from S. 
Chandarlapaty (Human Oncology & Pathogenesis Program, Memorial Sloan-
Kettering Cancer Center). CN34, MDA-MB-231 cells and their respective sub-
lines, LM1A and LM2, were propagated as previously described13,14,16. HEK293T, 
PANX1-null MEFs, MDA-MB-468 and WiDR cells were cultured in DMEM-based 
media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin 
and fungizone. BT549 and HCC1806 lines were cultured in RPMI-based media 
supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and 
fungizone. Sw480 cells were cultured in McCoy’s media supplemented with 10% 
FBS, glutamine, pyruvate, penicillin, streptomycin and fungizone. HUVEC cells 
were cultured as previously described15,16. All transfections were performed using 
Lipofectamine 2000 (Life Technologies). 
 
RNA sequencing, read alignment, allele frequency quantification and SNV 
calling—Total RNA was extracted using the MiRvana kit (Ambion) and reverse 
transcribed using the cDNA First-Strand Synthesis kit (Life Technologies). For 
whole-transcriptome sequencing, cDNA libraries were generated using the 
mRNA Sequencing Sample Preparation Kit (Illumina, 2009) according to the 
manufacturer’s instructions and sequencing-by-synthesis was performed using 
the GAIIx sequencer (Illumina). For read alignment, the quality of the reads 
generated by high-throughput sequencing was first examined using the FASTX 
toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). The reads were then trimmed 
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and filtered by quality and aligned against the human genome (release hg18) 
using the TopHat aligner79, which builds exon models de novo from the RNA-seq 
data and aligns reads across splice junctions. PCR duplicates that might interfere 
with SNV calling were removed. A statistical framework was then implemented to 
identify SNVs from the read alignments based on the assumption that biological 
variations will be found in a significant number of reads, while non-biological 
variations will not. A Poisson-Binomial distribution80 was used to calculate the p-
values of significance, taking into account the total number of reads at each 
genomic position, number of reads with mismatches, as well as the error rate at 
each sequencing cycle (e.g. typically the sequencing error is higher during later 
stages of sequencing). P-values were corrected for multiple hypotheses using 
the Benjamini-Hochberg method81 and the false discovery rate was controlled to 
1%. SNVs identified in less than 10 unique reads were removed from further 
analysis. The SNVs were also filtered to remove known single nucleotide 
polymorphisms (SNPs) reported in dbSNP (v130) and annotated with in-house 
programs (Elemento Laboratory, W.C.M.C., in preparation). Two additional 
computational algorithms (SNVmix82 and VarScan83)  independently validated 
these methods. SNV allelic ratios were calculated by dividing the number of 
unique reads containing a given variant by the total number of unique reads at 
each position20. Amino acid substitutions resulting from the nSNVs were ranked 
by the likelihood of being non-neutral using the computational tool PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/)23.  
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Allele-specific RNA-seq—Two-step PCR reactions of the PANX1 C268T 
allele in biological triplicates of each cell line were performed using the barcoded 
primers listed in Table 5. PCR amplicons were then sequenced using the 
HiSeq2000 (Illumina) platform. Position specific quantification of each allele was 
performed and used to calculate the PANX1 C268T allelic frequency of each cell 
line replicate.  
 
Sanger sequencing— Sanger sequencing was performed by GENEWIZ. 
Sequencing primers are listed in Table 5.  
 
Sequence Database Search—Clinical PANX1 mutations across human 
cancers were identified by searching the annotated variants provided by the 
Catalogue of Somatic Mutations in Cancer (COSMIC) and previous next-
generation sequencing studies84-88. 
 
Animal studies— All animal work was conducted in accordance with 
protocols approved by the Institutional Animal Care and Use Committee at The 
Rockefeller University. Seven- to eight-week-old age-matched female NOD/SCID 
mice were used for breast cancer tail-vein lung colonization- and systemic-
metastatic colonization assays14,16. Eight-week-old age-matched male 
NOD/SCID gamma mice were used for colon cancer liver metastatic colonization 
assays (through intrasplenic injection)16. PANX1-null mice (Shestopalov lab, 
University of Miami) were bred for the generation PANX1-null MEFs at embryonic 
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day 14 (E14). For the in vitro PANX1 inhibition metastasis assays, 1 × 105 LM1A 
or 4 × 104 LM2 cells in100 μl were incubated for 30 min with either 100 μM 
10Panx1 (Tocris), 100 μM scrambled peptide (Tocris), 500 μM Cbx (Sigma-
Aldrich) or an equivalent volume of PBS vehicle and injected intravenously into 
the lateral tail-vein. For the in vivo therapeutic PANX1 inhibition metastasis 
assays, mice were weighed, treated with Cbx or an equivalent volume of PBS by 
intraperitoneal injections at the indicated times and doses, and then tail-vein 
injected with 1 × 105 LM1A or 4 × 104 LM2 cells. For the PANX1 extracellular 
ATP release assays, 1 × 105 MDA-LM2 cells expressing plasma membrane-
anchored luciferase89 (LM2-pmeLUC) were preincubated with Cbx (500 μM) or 
an equivalent volume of PBS vehicle and injected into seven-week-old age-
matched female FVB/NJ mice. For orthotopic metastasis assays, two primary 
tumors per NSG mouse were generated through bilateral injections of 2.5 × 105 
MDA-MB-468 or 5.0 × 105 HCC1806 breast cancer cells into the lower mammary 
fat pads. The resulting tumors were measured every three days, size-matched, 
extracted at 100 mm3 and metastatic cell dissemination and colonization was 
noninvasively assayed through bioluminescence imaging as previously 
described14. For the long-term metastasis assays involving extracellular ATP 
depletion, 1 × 106 CN-LM1A cells expressing the plasma membrane-anchored 
extracellular ATP hydrolase CD39 or control vector, were injected into the lateral 
tail-vein of NS mice. For the acute extracellular ATP depletion assays, cells were 
preincubated with apyrase (2U/ml; NEB) or an equivalent volume of succinate 
buffer control and injected into seven-week-old age-matched female FVB/NJ 
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mice. For the truncated PANX1 in vivo metastasis assays, 5 × 105 cells (MDA-
MB-468, BT549, sw480 or WiDR) per 100 μl PBS were introduced intravenously 
through tail-vein (MDA-MB-468 and BT549) or intrasplenic (sw480 and WiDR) 
injections. Caspse activity was measured in vivo through retro-orbital injection of 
0.75 mg of VivoGloTM Caspase 3/7 Substrate (Z-DEVD-Aminoluciferine Sodium 
Salt) (Promega)90 per mouse.  
 
Generation of PANX1-null MEFs—MEFs from E14 PANX1-null embryos 
were generated as previously described91.  
 
Generation of retrovirus and stable overexpression cells—Generation of 
retroviral-overexpressing cells was performed as previously described14-16. 
Primers used to generate overexpression constructs are listed in Table 5. C-
terminus fluorescent protein-tagged PANX1, PANX11-89 and PANX1-L47fs*18 
were cloned into the respective pcDNA3-EGFP and pcDNA3-mRFP1 vectors 
with a GRPLE linker. Plasma-membrane anchored extracellular luciferase was 
cloned as previously described89. CD39 (clone 5762493, Open Biosystems) was 
stably expressed using the lentiviral pLenti vector system. For bioluminescent 
tracking of MDA-MB-468, BT549, HCC1806, sw480 and WiDR cancer lines, cells 
were labeled with a triple-fusion protein reporter construct as previously 
described5.  
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Analysis of mRNA expression—Expression of mRNA was quantified as 
described previously14. Primers can be found in Table 5.   
 
Immunofluorecence and confocal microscopy—Cells expressing 
fluorescently tagged proteins were fixed in 4% paraformaldehyde, stained with 
DAPI (Roche), mounted using ProLong Gold Antifade reagent (Life 
Technologies), and imaged using the Leica TCS SP5 II system. 
 
Immunoprecipitation and immunoblotting—Cellular lysates were prepared 
by lysing cells (10-40 million) overnight in ice-cold RIPA buffer containing 
protease and phosphatase inhibitors (Roche). The next day, cellular debris was 
removed by centrifugation (12,000 rpm) for 20 min at 4 °C. A 50 μL slurry of Anti-
FLAG M2 Magnetic Beads (Sigma-Aldrich) was added to the supernatant and 
rocked for 4 hrs at 4 °C. The beads were then washed three times with ice-cold 
lysis buffer. The immunoprecipitated proteins were eluted by denaturation in 
Laemmli buffer at 95 °C for 5 min, separated using SDS–PAGE, transferred to a 
PVDF membrane (Pierce), blocked and probed using a primary antibody to the 
N-terminal of PANX1 (1:1,000; ZMD.695 from Life Technologies). Bound 
antibodies were chemi-luminescently detected using horseradish peroxidase–
conjugated secondary antibodies (1:10,000), ECL Western Blotting Substrate 
(Pierce) and the SRX-101A (Konica Minolta) developer, according to the 
manufacturer’s instructions.  
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Protein crosslinking immunoprecipitation and immunoblotting—
Dithiobis[succinimidyl propionate] (DSP) was dissolved in anhydrous DMSO, 
diluted in PBS to formulate crosslinking solutions at the concentrations indicated, 
and used to crosslink cells in culture according to the manufacturer’s instructions 
(Pierce). Crosslinked cells were then washed twice in PBS and lysed using ice-
cold RIPA buffer supplemented with protease and phosphatase inhibitors 
(Roche). Lysates were collected by cell scraping, sonicated and rotated at 4 °C 
for 4-12 hrs. Cellular debris was removed by centrifugation (12,000 rpm) for 20 
min at 4 °C. Protein concentrations were measured using the BCA protein assay 
(Pierce). For immunoprecipitation of crosslinked proteins, a 50 μL slurry of Anti-
RFP Magnetic Beads (MBL International) was added to 200 μg protein lysates 
diluted in 750 μL Co-IP lysis buffer (Thermo Scientific)  and rocked for 4 hrs at 4 
°C. The beads were then washed three times in Co-IP lysis buffer, resuspended 
in Non-Reducing Lane Marker Sample Buffer (Thermo Scientific), boiled at 95 °C 
for 5 min, and separated using SDS-PAGE on a Novex 3-8% Tris-Acetate gel 
(Life Technologies). For crosslinked PANX1 complex immunoblotting, primary 
antibodies to PANX1 (1:1000; Life Technologies), GFP (1:1000, ab290 from 
Abcam) and RFP (1:1000; biotin conjugated ab34771 from Abcam) were used. 
Bound antibodies were chemi-luminescently detected using horseradish 
peroxidase–conjugated secondary antibodies, ECL Western Blotting Substrate 
(Pierce) and the SRX-101A (Konica Minolta) developer, according to the 
manufacturer’s instructions.  
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ATP release assays —Cells were seeded in quadruplicate at 100,000-
200,000 cells per well in 24-well plates and grown overnight. Each well was then 
washed with 200 μl PBS. For PANX1 inhibition, cells were incubated at room 
temperature for 10 min in PBS supplemented with one of the following reagents: 
Cbx (500 μM), PB (2 mM; Life Technologies), 10Panx1 (100 μM) or an equivalent 
dose of the appropriate vehicle control (100% PBS or scrambled peptide). The 
wash or pretreatment solution was then aspirated, replaced with 200 μM fresh 
100% PBS or 70% PBS (hypotonic stretch assays) for the indicated times, 
harvested and transferred to microcentrifuge tubes, and then spun at 1,000 rpm 
for 2 min at room temperature. Supernatants were transferred to 96-well plates 
and ATP was measured using the CellTiter-Glo Luminescent Cell Viability Assay 
(Promega) according to the manufacturer’s instructions. For hypotonic stretch 
assays, the numbers of viable cells remaining post-stretch were counted for each 
treatment condition to rule out the contribution of cell lysis to extracellular ATP 
levels. 
 
Histology—For histological quantification of single breast cancer cells, 
mice lungs were extracted at one and three days post cancer cell injection. By 
administering solutions through the heart and trachea, lungs were perfused and 
fixed with PBS and 4% paraformaldehyde, respectively. Frozen lung sections (10 
microns thick) were stained with an antibody raised against human vimentin 
(1:40, Vector Laboratories) and DAPI. Alexa Fluor 488 Dye (1:200, Life 
Technologies) was used to detect vimentin. Slices were mounted using ProLong 
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Gold Antifade Reagent (Life Technologies). For histological quantification of 
metastatic foci, mice lungs were extracted at the indicated time-points, perfused 
and fixed as above, and sent out for sectioning and H&E staining (Histoserv). 
Quantification of cells and metastatic foci in histological step-sections was 
performed in a blinded manner. For endothelial labeling, 100 mg of biotinlyated 
lectin dissolved in PBS was injected retro-orbitally and allowed to circulate for 5 
min prior to fixation. Mice were subsequently sacrificed, and their lungs were 
extracted without perfusion and fixed in 4% paraformaldehyde overnight. Frozen 
lung sections (10 microns thick) were stained with antibodies against human 
vimentin (1:40, Vector Laboratories) and cleaved caspase-3 (1:2000, Cell 
Signaling Technology). Primary antibodies were detected using Alexa-fluor dye-
conjugated secondary antibodies (1:200, Life Technologies.) Stained sections 
were mounted using ProLong Gold Antifade Reagent (Life Technologies). 
Images were obtained using Zeiss scanning laser confocal microscope (LSM 
510). 
 
Hypotonic deformation cell viability assays—Cells were seeded in 
quadruplicate at 100,000 cells per well in 24-well plates and grown overnight. 
When comparing wild-type and mutant PANX1-expressing cells, replicate plates 
of cells were counted at the time of the assay for normalization. Each well was 
then washed once with 200 μl 100% PBS. For PANX1 inhibition, cells were 
incubated with 100 μM 10Panx1 or scrambled peptides for 10 min in 100% PBS. 
The wash or pretreatment solution was then aspirated, and the cells were 
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stretched in 200 μl hypotonic solution (12.5% PBS) supplemented with the 
indicated reagents or vehicle controls for the times indicated. For ATP rescue 
experiments, 100 μM ATP (NEB) was added to the 10Panx1 hypotonic solution, 
and an equivalent volume of water was added to the control hypotonic solution. 
For pan-P2yR inhibition experiments, suramin (50 μM; Sigma-Aldrich) or water 
vehicle control was added to the pretreatment solution. For ATP depletion 
experiments, apyrase (2 U/ml) or an equivalent volume of succinate buffer 
control was added to the hypotonic solution. After deformation, the cells were 
gently washed twice with 100% PBS, trypsinized, stained with trypan blue 
(Sigma-Aldrich) and the remaining viable cells were quantified.  
 
Cancer cell proliferation—For molecular PANX1 inhibition assays, 5 × 103 
cancer cells overexpressing either the autoinhibitory C-terminal domain or control 
vector were seeded in quadruplicate in a 96 well plate in a 100 μl volume of 
DMEM-based containing 10% FBS. At days 0, 3, and 5, cells were trypsinized 
and viable cells were counted using a hemocytometer. Proliferation counts were 
normalized to day 0. For peptide inhibition proliferation assays, cancer cells were 
pretreated with 100 μM 10Panx1 peptide or vehicle for 15 min and seeded into 24 
well plates (25,000 cells/well) under the same conditions as pretreatment. After 
24 hrs, cancer cells were trypsinized and viable cells were counted using a 
hemocytometer. 
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Invasion assays—Invasion assays were performed as previously 
described16. Briefly, serum starved sub-lines were pretreated for 15 min with 100 
μM of 10Panx1 peptide or scrambled peptide in 0.2% FBS DMEM-based media, 
seeded onto Trans-well invasion chambers (BD Biosciences) under the same 
treatment conditions and incubated for 18-20 hrs. Cells that had invaded the 
inserts were counted in five fields per insert and then quantified using ImageJ. 
 
Transendothelial migration assays—Transendothelial migration assays 
were performed as previously described16. Briefly, serum starved Cell Tracker 
Green CMFDA-labeled (Life Technologies) MDA-LM2 cells were pretreated for 
15 min with 100 μM of 10Panx1 peptide or scrambled peptide in 0.2% FBS 
DMEM-based media, seeded on a monolayer of HUVEC cells under the same 
treatment conditions (50,000 cells/well) and incubated for 18 hrs. Migrated cells 
were counted in five fields per insert and then quantified using ImageJ.  
 
Anchorage-independent survival—Cancer cells (5,000 cells/well) were 
seeded in quadruplicate on 96-well Ultra-Low Attachment Surface plates 
(Corning) in the presence of 100 μM of 10Panx1 peptide or scrambled peptide in 
10% FBS DMEM-based media and incubated for 36 hours. Cell suspensions 
were then transferred to microcentrifuge tubes, isolated by centrifugation (1,000 
rpm) for 5 min, trypsinized and counted using a hemocytometer. 
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Statistical analysis and clinical validation of PANX1 expression—To 
determine the association between PANX1 gene expression and tumor grade, 
we used two independent datasets (expO and GSE5460) to stratify tumors based 
on BR-grades (high versus low) and employed one-tailed unpaired t-test to 
calculate the associated p-values. For Kaplan-Meier curves depicting 
associations between public datasets of breast47, lung47 and colon (GSE17536) 
tumor PANX1 expression and metastasis-free survival, an expression score 
greater or lower than the mean of the entire population was classified as high or 
low PANX1 expression, respectively. P-values are based on a Mantel-Cox log-
rank test. 
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Table 5. List of primers used in this study. 
 
 
 
 
Cloning primers Sequence
PANX1-F-EcoRI CGGAATTCATGGCCATCGCTCAACTG
PANX1-R-SalI ACGCGTCGACTCAGCAAGAAGAATCCAGAAGTC
PANX1(1-89)-R-SalI ACGCGTCGACCTACTGAACAGCCGCCCAGCAATA
PANX1-FLG-R_SalI ACGCGTCGACTCACTTGTCATCGTCGTCCTTGTAGTCGCAAGAAGAATCCAGAAGTC
(1-89)-FLG_R_salI ACGCGTCGACTCACTTGTCATCGTCGTCCTTGTAGTCCTGAACAGCCGCCCAGCAATA
PANX1(Ct)-Fwd CGGAATTCatgCCATTCCGACAGAAGACAGAT
PANX1_Fluoro_F CGGGATCCATGGCCATCGCTCAACTG
PANX1_WT-GFP_R GCGGCCGCCCGCAAGAAGAATCCAGAAGTC
PANX1_Q90-RFP_R GCGGCCGCCCCTGAACAGCCGCCCAGCAATA
Px1_L47fs-RFP_R GCGGCCGCCCTCTGTGTACCAATCGAGATC
CD39_F GGATCCATGGAAAGTGAAGAGTTGGCAGA
CD39_R GAATTCCTATACCATATCTTTCCAGAA
PANX1-delCt-R ACGCGTCGACCTAAACAAACAGCGTGTAGACAACCA
Sequencing primers Sequence
PANX1_C268-F GCCATGGCCATCGCTCAACT
PANX1_C268-R GGCTTTCAGATACCTCCCACAA
PANX1_gDNA-F CTGTTGGGAGGTTTGCAGTCGTG
PANX1_gDNA-R AGATACAGCACTGGTTGGCTACAA
KRIT1-F GAAAAACAGATTGAAGACCCACTA
KRIT1-R ACCACGAGACCAGCCTGTTTTGTA
RBFA-F CCTGAGGAATGTGCCACCGATAGT
RBFA-R TCCTCTGTTCTGCCACCTCCTCTC
REST-F AGAGCCTCCCCTTCACA
REST-R CGAGCCCCATGCAATCCAGA
ZSWIM6-F AGCCACTTGCAGCACATTATCAGC
ZSWIM6-R CAGCGAGGGTAGCGGTTGG
PANX1-seg-1-F GCGCCCGGCCGGTGACTGG
PANX1-seg-1-R AACTTGGGCTCCGTGGGCTCCTTC
PANX1-seg-2-F CCGGCCGGTGACTGGGTGAAGG
PANX1-seg-2-R GCGAAGGCCAGCGAGATGAGCA
PANX1-seg-3-F GAGCCCACGGAGCCCAAGTTCAAG
PANX1-seg-3-R TCGCAAAGAGCAGCAGGATGTAGG
Allele Specific Primers
asC268T-F TCCCTACACGACGCTCTTCCGATCTATTACGCGCTTTGTGGATTCATATTGC 
asC268T-R GTTCAGACGTGTGCTCTTCCGATCTGGGAGGTTTCCAGACTCG 
Illumina_C268T-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT
Illumina_C268T-R CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
Quickchange Primers
PANX1-136delC_QC-F GGACAAGATGGTCACGTGCATTGCGGTGGGGCTGCCCTGCTGCTCATCTCGCTGGCCTTCGCGCAGG
PANX1-136delC_QC-R CCTGCGCGAAGGCCAGCGAGATGAGCAGCAGGGCAGCCCCACCGCAATGCACGTGACCATCTTGTCC
Casp-Res-F GGCATGATCAAGATGGCTGTTGTTGCTGGCAAAACTCCCATG
Casp-Res-R CATGGGAGTTTTGCCAGCAACAACAGCCATCTTGATCATGCC
C265R-F GCCCGATCAGTTTCAGCGCAAACTCATTGCCGT
C265R-R ACGGCAATGAGTTTGCGCTGAAACTGATCGGGC
R217H-F CAAGTACATTAGCTGCCACCTGCTGACACTCATCA
R217H-R TGATGAGTGTCAGCAGGTGGCAGCTAATGTACTTG
L421H-F GAATGCCCGACAGAGACATCTGGATTCTTCTTGCT
L421H-R AGCAAGAAGAATCCAGATGTCTCTGTCGGGCATTC
V290M-F TCCTGCTGGCTCCCATGGTTGTCTACACG
V290M-R CGTGTAGACAACCATGGGAGCCAGCAGGA
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